1
|
Lê H, Deforges J, Cutolo P, Lamarque A, Hua G, Lindner V, Jain S, Balloul JM, Benkirane-Jessel N, Quéméneur E. Patient-derived tumoroids and proteomic signatures: tools for early drug discovery. Front Immunol 2024; 15:1379613. [PMID: 38698850 PMCID: PMC11063793 DOI: 10.3389/fimmu.2024.1379613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 03/14/2024] [Indexed: 05/05/2024] Open
Abstract
Onco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties. In this study, we evaluated onco-virotherapy in vitro responses on immunocompetent non-small cell lung cancer (NSCLC) patient-derived tumoroids (PDTs) and healthy organoids. PDTs are accurate tools to predict patient's clinical responses at the in vitro stage. We showed that onco-virotherapy could exert specific antitumoral effects by producing a higher number of viral particles in PDTs than in healthy organoids. In the present work, we used multiplex protein screening, based on proximity extension assay to highlight different response profiles. Our results pointed to the increase of proteins implied in T cell activation, such as IFN-γ following onco-virotherapy treatment. Based on our observation, oncolytic viruses-based therapy responders are dependent on several factors: a high PD-L1 expression, which is a biomarker of greater immune response under immunotherapies, and the number of viral particles present in tumor tissue, which is dependent to the metabolic state of tumoral cells. Herein, we highlight the use of PDTs as an alternative in vitro model to assess patient-specific responses to onco-virotherapy at the early stage of the preclinical phases.
Collapse
Affiliation(s)
- Hélène Lê
- Transgene S.A., Illkirch–Graffenstaden, France
- INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France
| | | | | | | | - Guoqiang Hua
- INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France
| | - Véronique Lindner
- INSERM UMR1260, Regenerative Nanomedicine, Strasbourg, France
- Department of Pathology, Hopitaux Universitaires de Strasbourg, Strasbourg, France
| | | | | | | | | |
Collapse
|
2
|
Vignes H, Smaida R, Conzatti G, Hua G, Benkirane-Jessel N. Custom-made meniscus biofabrication. Trends Biotechnol 2023; 41:1467-1470. [PMID: 37423883 DOI: 10.1016/j.tibtech.2023.06.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 06/12/2023] [Accepted: 06/12/2023] [Indexed: 07/11/2023]
Abstract
Reconstructing the meniscus is not currently possible due to its intricate and heterogeneous structure. In this forum, we first discuss the shortcomings of current clinical strategies in meniscus repair. Then, we describe a new promising cell-based, ink-free 3D biofabrication technology to produce tailor-made large-scale functional menisci.
Collapse
Affiliation(s)
- Hélène Vignes
- French National Institute of Health and Medical Research (INSERM), UMR 1260, Regenerative Nanomedicine (RNM), 1 Rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg (Faculté de Médecine, Faculté de Chirurgie Dentaire, Faculté de Pharmacie), Strasbourg, France
| | - Rana Smaida
- French National Institute of Health and Medical Research (INSERM), UMR 1260, Regenerative Nanomedicine (RNM), 1 Rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg (Faculté de Médecine, Faculté de Chirurgie Dentaire, Faculté de Pharmacie), Strasbourg, France
| | - Guillaume Conzatti
- French National Institute of Health and Medical Research (INSERM), UMR 1260, Regenerative Nanomedicine (RNM), 1 Rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg (Faculté de Médecine, Faculté de Chirurgie Dentaire, Faculté de Pharmacie), Strasbourg, France
| | - Guoqiang Hua
- French National Institute of Health and Medical Research (INSERM), UMR 1260, Regenerative Nanomedicine (RNM), 1 Rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg (Faculté de Médecine, Faculté de Chirurgie Dentaire, Faculté de Pharmacie), Strasbourg, France
| | - Nadia Benkirane-Jessel
- French National Institute of Health and Medical Research (INSERM), UMR 1260, Regenerative Nanomedicine (RNM), 1 Rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg (Faculté de Médecine, Faculté de Chirurgie Dentaire, Faculté de Pharmacie), Strasbourg, France.
| |
Collapse
|
3
|
Lê H, Deforges J, Hua G, Idoux-Gillet Y, Ponté C, Lindner V, Olland A, Falcoz PE, Zaupa C, Jain S, Quéméneur E, Benkirane-Jessel N, Balloul JM. In vitro vascularized immunocompetent patient-derived model to test cancer therapies. iScience 2023; 26:108094. [PMID: 37860774 PMCID: PMC10582498 DOI: 10.1016/j.isci.2023.108094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/21/2023] [Accepted: 09/26/2023] [Indexed: 10/21/2023] Open
Abstract
This work describes a patient-derived tumoroid model (PDTs) to support precision medicine in lung oncology. The use of human adipose tissue-derived microvasculature and patient-derived peripheral blood mononuclear cells (PBMCs) permits to achieve a physiologically relevant tumor microenvironment. This study involved ten patients at various stages of tumor progression. The vascularized, immune-infiltrated PDT model could be obtained within two weeks, matching the requirements of the therapeutic decision. Histological and transcriptomic analyses confirmed that the main features from the original tumor were reproduced. The 3D tumor model could be used to determine the dynamics of response to antiangiogenic therapy and platinum-based chemotherapy. Antiangiogenic therapy showed a significant decrease in vascular endothelial growth factor (VEGF)-A expression, reflecting its therapeutic effect in the model. In an immune-infiltrated PDT model, chemotherapy showed the ability to decrease the levels of lymphocyte activation gene-3 protein (LAG-3), B and T lymphocyte attenuator (BTLA), and inhibitory receptors of T cells functions.
Collapse
Affiliation(s)
- Hélène Lê
- Transgene S.A, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Jules Deforges
- Transgene S.A, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
| | - Guoqiang Hua
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Ysia Idoux-Gillet
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Charlotte Ponté
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
- Hopitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Véronique Lindner
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Anne Olland
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
- Hopitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Pierre-Emanuel Falcoz
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
- Hopitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Cécile Zaupa
- Boehringer Ingelheim, 29 avenue Tony Garnier, 69007 Lyon, France
| | - Shreyansh Jain
- Transgene S.A, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
| | - Eric Quéméneur
- Transgene S.A, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
| | - Nadia Benkirane-Jessel
- INSERM UMR 1260, Regenerative Nanomedicine, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Jean-Marc Balloul
- Transgene S.A, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
| |
Collapse
|
4
|
Nounsi A, Seitlinger J, Ponté C, Demiselle J, Idoux-Gillet Y, Pencreach E, Beau-Faller M, Lindner V, Balloul JM, Quemeneur E, Burckel H, Noël G, Olland A, Fioretti F, Falcoz PE, Benkirane-Jessel N, Hua G. Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer. Biomedicines 2023; 11:1824. [PMID: 37509464 PMCID: PMC10376341 DOI: 10.3390/biomedicines11071824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 06/19/2023] [Accepted: 06/20/2023] [Indexed: 07/30/2023] Open
Abstract
Radiation therapy and platinum-based chemotherapy are common treatments for lung cancer patients. Several factors are considered for the low overall survival rate of lung cancer, such as the patient's physical state and the complex heterogeneity of the tumor, which leads to resistance to the treatment. Consequently, precision medicines are needed for the patients to improve their survival and their quality of life. Until now, no patient-derived tumoroid model has been reported to predict the efficiency of radiation therapy in non-small-cell lung cancer. Using our patient-derived tumoroid model, we report that this model could be used to evaluate the efficiency of radiation therapy and cisplatin-based chemotherapy in non-small-cell lung cancer. In addition, these results can be correlated to clinical outcomes of patients, indicating that this patient-derived tumoroid model can predict the response to radiotherapy and chemotherapy in non-small-cell lung cancer.
Collapse
Affiliation(s)
- Anasse Nounsi
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Faculty of Dental Surgery, Strasbourg University Hospital (HUS), University of Strasbourg, 8 Rue de Ste. Elisabeth, 67000 Strasbourg, France
| | - Joseph Seitlinger
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
| | - Charlotte Ponté
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
| | - Julien Demiselle
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Department of Medical Intensive Care, Strasbourg University Hospital (HUS), 1 Place de l'Hôpital, 67000 Strasbourg, France
| | - Ysia Idoux-Gillet
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Faculty of Dental Surgery, Strasbourg University Hospital (HUS), University of Strasbourg, 8 Rue de Ste. Elisabeth, 67000 Strasbourg, France
| | - Erwan Pencreach
- Department of Biochemistry and Molecular Biology, Strasbourg University Hospital (HUS), 67098 Strasbourg, France
| | - Michèle Beau-Faller
- Department of Biochemistry and Molecular Biology, Strasbourg University Hospital (HUS), 67098 Strasbourg, France
| | - Véronique Lindner
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Department of Pathology, Strasbourg University Hospital (HUS), 1 Place de l'Hôpital, 67000 Strasbourg, France
| | - Jean-Marc Balloul
- Transgene SA, 400 Boulevard Gonthier d'Andernach-Parc d'Innovation-CS80166, 67405 Illkirch Graffenstaden, France
| | - Eric Quemeneur
- Transgene SA, 400 Boulevard Gonthier d'Andernach-Parc d'Innovation-CS80166, 67405 Illkirch Graffenstaden, France
| | - Hélène Burckel
- Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, 67200 Strasbourg, France
- Radiobiology Laboratory, Paul Strauss Comprehensive Cancer Center, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67033 Strasbourg, France
- ICube Laboratory, 300 Bd Sébastien Brant, 67400 Illkirch-Graffenstaden, France
| | - Georges Noël
- Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, 67200 Strasbourg, France
- Radiobiology Laboratory, Paul Strauss Comprehensive Cancer Center, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67033 Strasbourg, France
- ICube Laboratory, 300 Bd Sébastien Brant, 67400 Illkirch-Graffenstaden, France
| | - Anne Olland
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Lung Transplantation Group, Thoracic Surgery Department, Strasbourg University Hospital (HUS), 1 Place de l'Hôpital, 67000 Strasbourg, France
| | - Florence Fioretti
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Faculty of Dental Surgery, Strasbourg University Hospital (HUS), University of Strasbourg, 8 Rue de Ste. Elisabeth, 67000 Strasbourg, France
| | - Pierre-Emmanuel Falcoz
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Lung Transplantation Group, Thoracic Surgery Department, Strasbourg University Hospital (HUS), 1 Place de l'Hôpital, 67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Faculty of Dental Surgery, Strasbourg University Hospital (HUS), University of Strasbourg, 8 Rue de Ste. Elisabeth, 67000 Strasbourg, France
| | - Guoqiang Hua
- Regenerative Nanomedicine Unit, Center of Research on Biomedicines of Strasbourg (CRBS), French National Institute of Health and Medical Research (INSERM), University of Strasbourg, UMR 1260, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
- Faculty of Dental Surgery, Strasbourg University Hospital (HUS), University of Strasbourg, 8 Rue de Ste. Elisabeth, 67000 Strasbourg, France
| |
Collapse
|
5
|
Batool F, Gegout PY, Stutz C, White B, Kolodziej A, Benkirane-Jessel N, Petit C, Huck O. Lenabasum Reduces Porphyromonas gingivalis-Driven Inflammation. Inflammation 2022; 45:1752-1764. [PMID: 35274214 DOI: 10.1007/s10753-022-01658-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 03/03/2022] [Accepted: 03/07/2022] [Indexed: 01/05/2023]
Abstract
The aim of this study was to evaluate the potential anti-inflammatory and anti-resorptive effects of lenabasum in the context of Porphyromonas gingivalis (Pg)-induced inflammation. Lenabasum or ajulemic acid (1',1'-dimethylheptyl-THC-11-oic-acid), a synthetic analog of THC-11-oic acid, has already demonstrated anti-inflammatory properties for the treatment of several inflammatory diseases. In vitro, the cytocompatibility of lenabasum was evaluated in human oral epithelial cells (EC), oral fibroblasts and osteoblasts by metabolic activity assay. The effect of lenabasum (5 µM) treatment of Pg-LPS- and P. gingivalis-infected EC on the pro- and anti-inflammatory markers was studied through RTqPCR. In vivo, lenabasum was injected subcutaneously in a P. gingivalis-induced calvarial abscess mouse model to assess its pro-healing effect. Concentrations of lenabasum up to 5 µM were cytocompatible in all cell types. Treatment of Pg-LPS and Pg-infected EC with lenabasum (5 µM; 6 h) reduced the gene expression of TNF-α, COX-2, NF-κB, and RANKL, whereas it increased the expression of IL-10 and resolvin E1 receptor respectively (p < 0.05). In vivo, the Pg-elicited inflammatory lesions' clinical size was significantly reduced by lenabasum injection (30 µM) vs untreated controls (45%) (p < 0.05). Histomorphometric analysis exhibited improved quantity and quality of bone (with reduced lacunae) and significantly reduced calvarial soft tissue inflammatory score in mice treated with lenabasum (p < 0.05). Tartrate-resistant acid phosphatase activity assay (TRAP) also demonstrated decreased osteoclastic activity in the treatment group compared to that in the controls. Lenabasum showed promising anti-inflammatory and pro-resolutive properties in the management of Pg-elicited inflammation, and thus, its potential as adjuvant periodontal treatment should be further investigated.
Collapse
Affiliation(s)
- Fareeha Batool
- Faculté de Chirurgie-Dentaire, Université de Strasbourg, 8 rue Sainte-Elisabeth, 67000, Strasbourg, France.,UMR 1260, Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM (French National Institute of Health and Medical Research), Regenerative Nanomedicine, Strasbourg, France
| | - Pierre-Yves Gegout
- Faculté de Chirurgie-Dentaire, Université de Strasbourg, 8 rue Sainte-Elisabeth, 67000, Strasbourg, France
| | - Céline Stutz
- Faculté de Chirurgie-Dentaire, Université de Strasbourg, 8 rue Sainte-Elisabeth, 67000, Strasbourg, France.,UMR 1260, Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM (French National Institute of Health and Medical Research), Regenerative Nanomedicine, Strasbourg, France
| | | | | | - Nadia Benkirane-Jessel
- UMR 1260, Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM (French National Institute of Health and Medical Research), Regenerative Nanomedicine, Strasbourg, France
| | - Catherine Petit
- Faculté de Chirurgie-Dentaire, Université de Strasbourg, 8 rue Sainte-Elisabeth, 67000, Strasbourg, France.,UMR 1260, Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM (French National Institute of Health and Medical Research), Regenerative Nanomedicine, Strasbourg, France.,Pôle de Médecine Et Chirurgie Bucco-Dentaire, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France
| | - Olivier Huck
- Faculté de Chirurgie-Dentaire, Université de Strasbourg, 8 rue Sainte-Elisabeth, 67000, Strasbourg, France. .,UMR 1260, Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM (French National Institute of Health and Medical Research), Regenerative Nanomedicine, Strasbourg, France. .,Pôle de Médecine Et Chirurgie Bucco-Dentaire, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France.
| |
Collapse
|
6
|
Lê H, Seitlinger J, Lindner V, Olland A, Falcoz PE, Benkirane-Jessel N, Quéméneur E. Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine. Biomedicines 2022; 10:biomedicines10071677. [PMID: 35884982 PMCID: PMC9312903 DOI: 10.3390/biomedicines10071677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 07/08/2022] [Accepted: 07/10/2022] [Indexed: 11/16/2022] Open
Abstract
Synthetic 3D multicellular systems derived from patient tumors, or tumoroids, have been developed to complete the cancer research arsenal and overcome the limits of current preclinical models. They aim to represent the molecular and structural heterogeneity of the tumor micro-environment, and its complex network of interactions, with greater accuracy. They are more predictive of clinical outcomes, of adverse events, and of resistance mechanisms. Thus, they increase the success rate of drug development, and help clinicians in their decision-making process. Lung cancer remains amongst the deadliest of diseases, and still requires intensive research. In this review, we analyze the merits and drawbacks of the current preclinical models used in lung cancer research, and the position of tumoroids. The introduction of immune cells and healthy regulatory cells in autologous tumoroid models has enabled their application to most recent therapeutic concepts. The possibility of deriving tumoroids from primary tumors within reasonable time has opened a direct approach to patient-specific features, supporting their future role in precision medicine.
Collapse
Affiliation(s)
- Hélène Lê
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (H.L.); (J.S.); (V.L.); (A.O.); (P.-E.F.); (N.B.-J.)
- Transgène SA, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
| | - Joseph Seitlinger
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (H.L.); (J.S.); (V.L.); (A.O.); (P.-E.F.); (N.B.-J.)
- Faculty of Medicine and Pharmacy, University Hospital Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Véronique Lindner
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (H.L.); (J.S.); (V.L.); (A.O.); (P.-E.F.); (N.B.-J.)
- Faculty of Medicine and Pharmacy, University Hospital Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Anne Olland
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (H.L.); (J.S.); (V.L.); (A.O.); (P.-E.F.); (N.B.-J.)
- Faculty of Medicine and Pharmacy, University Hospital Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Pierre-Emmanuel Falcoz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (H.L.); (J.S.); (V.L.); (A.O.); (P.-E.F.); (N.B.-J.)
- Faculty of Medicine and Pharmacy, University Hospital Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (H.L.); (J.S.); (V.L.); (A.O.); (P.-E.F.); (N.B.-J.)
- Faculty of Medicine and Pharmacy, University Hospital Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Eric Quéméneur
- Transgène SA, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
- Correspondence:
| |
Collapse
|
7
|
Seitlinger J, Nounsi A, Idoux-Gillet Y, Santos Pujol E, Lê H, Grandgirard E, Olland A, Lindner V, Zaupa C, Balloul JM, Quemeneur E, Massard G, Falcoz PE, Hua G, Benkirane-Jessel N. Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment. Biomedicines 2022; 10:biomedicines10051103. [PMID: 35625840 PMCID: PMC9138465 DOI: 10.3390/biomedicines10051103] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/04/2022] [Accepted: 05/05/2022] [Indexed: 02/04/2023] Open
Abstract
Patient-derived tumoroid (PDT) has been developed and used for anti-drug screening in the last decade. As compared to other existing drug screening models, a PDT-based in vitro 3D cell culture model could preserve the histological and mutational characteristics of their corresponding tumors and mimic the tumor microenvironment. However, few studies have been carried out to improve the microvascular network connecting the PDT and its surrounding microenvironment, knowing that poor tumor-selective drug transport and delivery is one of the major reasons for both the failure of anti-cancer drug screens and resistance in clinical treatment. In this study, we formed vascularized PDTs in six days using multiple cell types which maintain the histopathological features of the original cancer tissue. Furthermore, our results demonstrated a vascular network connecting PDT and its surrounding microenvironment. This fast and promising PDT model opens new perspectives for personalized medicine: this model could easily be used to test all therapeutic treatments and could be connected with a microfluidic device for more accurate drug screening.
Collapse
Affiliation(s)
- Joseph Seitlinger
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- 1 Place de l’Hôpital, University Hospital Strasbourg (HUS), 67000 Strasbourg, France
| | - Anasse Nounsi
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- Faculty of Dental Surgery, University of Strasbourg, 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- Faculty of Dental Surgery, University of Strasbourg, 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
| | - Eloy Santos Pujol
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- Faculty of Dental Surgery, University of Strasbourg, 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
| | - Hélène Lê
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- Faculty of Dental Surgery, University of Strasbourg, 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
- Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France; (C.Z.); (J.-M.B.); (E.Q.)
| | - Erwan Grandgirard
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS, UMR 7104, Inserm U 1258, 1 rue Laurent Fries, BP 10142, 67404 Illkirch Graffenstaden, France;
| | - Anne Olland
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- 1 Place de l’Hôpital, University Hospital Strasbourg (HUS), 67000 Strasbourg, France
| | - Véronique Lindner
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- 1 Place de l’Hôpital, University Hospital Strasbourg (HUS), 67000 Strasbourg, France
| | - Cécile Zaupa
- Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France; (C.Z.); (J.-M.B.); (E.Q.)
| | - Jean-Marc Balloul
- Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France; (C.Z.); (J.-M.B.); (E.Q.)
| | - Eric Quemeneur
- Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France; (C.Z.); (J.-M.B.); (E.Q.)
| | - Gilbert Massard
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- 1 Place de l’Hôpital, University Hospital Strasbourg (HUS), 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
| | - Pierre-Emmanuel Falcoz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- 1 Place de l’Hôpital, University Hospital Strasbourg (HUS), 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
| | - Guoqiang Hua
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- Faculty of Dental Surgery, University of Strasbourg, 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France; (J.S.); (A.N.); (Y.I.-G.); (E.S.P.); (H.L.); (A.O.); (V.L.); (G.M.); (P.-E.F.); (G.H.)
- Faculty of Dental Surgery, University of Strasbourg, 67000 Strasbourg, France
- Faculty of medicine, University of Strasbourg, 67000 Strasbourg, France
- Correspondence:
| |
Collapse
|
8
|
Batool F, Petit C, Stutz C, Özçelik H, Gegout PY, Benkirane-Jessel N, Delpy E, Zal F, Leize-Zal E, Huck O. M101, a therapeutic oxygen carrier derived from Arenicola marina, decreased Porphyromonas gingivalis induced hypoxia and improved periodontal healing. J Periodontol 2022; 93:1712-1724. [PMID: 35536914 DOI: 10.1002/jper.22-0006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 04/13/2022] [Accepted: 04/22/2022] [Indexed: 11/06/2022]
Abstract
BACKGROUND P. gingivalis exacerbates tissue hypoxia and worsens periodontal inflammation. This study investigated the effect of a therapeutic oxygen carrier (M101), derived from Arenicola marina, on hypoxia and associated inflammation in the context of periodontitis. METHODS The effect of M101 on GLUT-1, GLUT-3, HIF-1α and MMP-9 expression, hypoxia and antioxidant status in oral epithelial cells (EC) exposed to CoCl2 (1000μM), P. gingivalis (MOI 100) and CoCl2 + P. gingivalis was evaluated through hypoxia detection fluorescence assay, antioxidant concentration colorimetric assay and RTqPCR. Evaluation of M101 on EC proliferation was evaluated in an in vitro wound assay. In experimental periodontitis, periodontal wound healing and osteoclastic activity were compared among natural wound healing, placebo and gels containing M101 (1 g/L and 2 g/L) groups through histomorphometry and TRAP assay respectively. The expression of HIF-1α, MMP-9 and NFκB in periodontal tissues was also evaluated through immunofluorescence studies. RESULTS M101 downregulated GLUT-1, GLUT-3, HIF-1α and MMP-9 levels in EC exposed to CoCl2 , P. gingivalis and CoCl2 + P. gingivalis (p < 0.05). Fluorescence and colorimetric analyses confirmed hypoxia reduction and antioxidant capacity improvement in such EC upon M101 treatment. Moreover, M101 improved significantly the in vitro wound closure. In vivo, the attachment level was significantly improved, and osteoclastic activity was reduced in mice treated with M101 gels compared to placebo and natural wound healing groups (p < 0.05). HIF-1α, MMP-9 and NFκB expression in periodontal tissues was reduced in M101 gels treated mice compared to the controls. CONCLUSION M101 showed promise in resolving hypoxia and associated inflammation mediated tissue degradation. Its potential in the clinical management of periodontitis must be further investigated. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Fareeha Batool
- University of Strasbourg, Dental Faculty, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - Catherine Petit
- University of Strasbourg, Dental Faculty, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France.,University hospital, Strasbourg, France
| | - Céline Stutz
- University of Strasbourg, Dental Faculty, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - Hayriye Özçelik
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - Pierre-Yves Gegout
- University of Strasbourg, Dental Faculty, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France.,HEMARINA SA, Morlaix, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | | | | | | | - Olivier Huck
- University of Strasbourg, Dental Faculty, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Strasbourg, France.,HEMARINA SA, Morlaix, France
| |
Collapse
|
9
|
Naja M, Fernandez De Grado G, Favreau H, Scipioni D, Benkirane-Jessel N, Musset AM, Offner D. Comparative effectiveness of nonsurgical interventions in the treatment of patients with knee osteoarthritis: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore) 2021; 100:e28067. [PMID: 34889254 PMCID: PMC8663883 DOI: 10.1097/md.0000000000028067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 11/11/2021] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND To find out, based on the available recent randomized controlled trials (RCTs), if the nonsurgical interventions commonly used for knee osteoarthritis patients are valid and quantify their efficiency. METHODS The database of MEDLINE and EMBASE were searched for RCTs evaluating nonsurgical treatment strategies on patients with mild to moderate knee osteoarthritis. A Bayesian random-effects network meta-analysis was performed. The primary outcome was the mean change from baseline in the Western Ontario and McMaster university (WOMAC) total score at 12 months. Raw mean differences with 95% credibility intervals were calculated. Treatments were ranked by probabilities of each treatment to be the best. RESULTS Thirteen trials assessed 7 strategies with WOMAC at 12 months: injection of platelet rich plasma (PRP), corticosteroids, mesenchymal stem cells (MSCs), hyaluronic acid, ozone, administration of nonsteroidal anti-inflammatory drugs with or without the association of physiotherapy. For treatment-specific effect size, a greater association with WOMAC decrease was found significantly for MSCs (mean difference, -28.0 [95% CrI, -32.9 to -22.4]) and PRP (mean difference, -19.9 [95% CrI, -24.1 to -15.8]). Rank probabilities among the treatments indicated that MSCs had a much higher probability (P = .91) of being the best treatment compared with other treatments, while PRP ranked as the second-best treatment (P = .89). CONCLUSION In this systematic review and network meta-analysis, the outcomes of treatments using MSCs and PRP for the management of knee osteoarthritis were associated with long-term improvements in pain and function. More high quality RCTs would be needed to confirm the efficiency of MSCs and PRP for the treatment of patients with knee osteoarthritis.
Collapse
Affiliation(s)
- Moustafa Naja
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
- Université de Strasbourg, Faculty of dental surgery, 8 street Ste Elisabeth F-67000 Strasbourg, France
| | - Gabriel Fernandez De Grado
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
- Université de Strasbourg, Faculty of dental surgery, 8 street Ste Elisabeth F-67000 Strasbourg, France
- Oral Medicine and Surgery Department, Strasbourg University hospital, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Henri Favreau
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
- Strasbourg University hospital, Hautepierre Hospital, Orthopedic Surgery and Traumatology Department, 1 Avenue Molière, 67200 Strasbourg, France
| | - Dominique Scipioni
- Erasme Hospital- University Clinics of Brussels, Université libre de Bruxelles (ULB), CHIREC-Hospital Delta, Belgium
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
- Université de Strasbourg, Faculty of dental surgery, 8 street Ste Elisabeth F-67000 Strasbourg, France
| | - Anne-Marie Musset
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
- Université de Strasbourg, Faculty of dental surgery, 8 street Ste Elisabeth F-67000 Strasbourg, France
- Oral Medicine and Surgery Department, Strasbourg University hospital, 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Damien Offner
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
- Université de Strasbourg, Faculty of dental surgery, 8 street Ste Elisabeth F-67000 Strasbourg, France
- Oral Medicine and Surgery Department, Strasbourg University hospital, 1 Place de l’Hôpital, 67000 Strasbourg, France
| |
Collapse
|
10
|
Huck O, Stutz C, Gegout PY, Özçelik H, Benkirane-Jessel N, Petit C, Batool F. Nanomedicine and Periodontal Regenerative Treatment. Dent Clin North Am 2021; 66:131-155. [PMID: 34794551 DOI: 10.1016/j.cden.2021.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Current periodontal treatments aim to control bacterial infection and decrease inflammation. To optimize contemporary conventional treatments that present limitations owing to an inability to reach the lesion site, new methods are based on nanomedicine. Nanomedecine allows delivery of host-modulatory drugs or antibacterial molecules at the lesion site in an optimal concentration with decreased toxicity and risk of systemic side effects. Chitosan and polylactic-co-glycolic acid-loaded nanoparticles, carbon quantum dots, and mesoporous silicates open new perspectives in periodontitis management. The potential therapeutic impact of the main nanocarriers is discussed.
Collapse
Affiliation(s)
- Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France; Pôle de médecine et chirurgie bucco-dentaire, Hôpitaux Universitaires de Strasbourg, Periodontology, 1 place de l'Hopital, 67000, Strasbourg, France.
| | - Céline Stutz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Pierre-Yves Gegout
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France; Pôle de médecine et chirurgie bucco-dentaire, Hôpitaux Universitaires de Strasbourg, Periodontology, 1 place de l'Hopital, 67000, Strasbourg, France
| | - Hayriye Özçelik
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Catherine Petit
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France; Pôle de médecine et chirurgie bucco-dentaire, Hôpitaux Universitaires de Strasbourg, Periodontology, 1 place de l'Hopital, 67000, Strasbourg, France
| | - Fareeha Batool
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France
| |
Collapse
|
11
|
Hsu PY, Mammadova A, Benkirane-Jessel N, Désaubry L, Nebigil CG. Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies. Front Cardiovasc Med 2021; 8:694711. [PMID: 34386529 PMCID: PMC8353082 DOI: 10.3389/fcvm.2021.694711] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 06/18/2021] [Indexed: 12/11/2022] Open
Abstract
Vascular toxicity is a frequent adverse effect of current anticancer chemotherapies and often results from endothelial dysfunction. Vascular endothelial growth factor inhibitors (VEGFi), anthracyclines, plant alkaloids, alkylating agents, antimetabolites, and radiation therapy evoke vascular toxicity. These anticancer treatments not only affect tumor vascularization in a beneficial manner, they also damage ECs in the heart. Cardiac ECs have a vital role in cardiovascular functions including hemostasis, inflammatory and coagulation responses, vasculogenesis, and angiogenesis. EC damage can be resulted from capturing angiogenic factors, inhibiting EC proliferation, survival and signal transduction, or altering vascular tone. EC dysfunction accounts for the pathogenesis of myocardial infarction, atherothrombosis, microangiopathies, and hypertension. In this review, we provide a comprehensive overview of the effects of chemotherapeutic agents on vascular toxicity leading to hypertension, microvascular rarefaction thrombosis and atherosclerosis, and affecting drug delivery. We also describe the potential therapeutic approaches such as vascular endothelial growth factor (VEGF)-B and prokineticin receptor-1 agonists to maintain endothelial function during or following treatments with chemotherapeutic agents, without affecting anti-tumor effectiveness.
Collapse
Affiliation(s)
| | | | | | | | - Canan G. Nebigil
- INSERM UMR 1260, Regenerative Nanomedicine, University of Strasbourg, FMTS (Fédération de Médecine Translationnelle de l'Université de Strasbourg), Strasbourg, France
| |
Collapse
|
12
|
Bugueno IM, Benkirane-Jessel N, Huck O. Implication of Toll/IL-1 receptor domain containing adapters in Porphyromonas gingivalis-induced inflammation. Innate Immun 2021; 27:324-342. [PMID: 34018827 PMCID: PMC8186158 DOI: 10.1177/17534259211013087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Periodontitis is induced by periodontal dysbiosis characterized by the predominance of anaerobic species. TLRs constitute the classical pathway for cell activation by infection. Interestingly, the Toll/IL-1 receptor homology domain adapters initiate signaling events, leading to the activation of the expression of the genes involved in the host immune response. The aim of this study was to evaluate the effects of Porphyromonas gingivalis on the expression and protein-protein interactions among five TIR adapters (MAL, MyD88, TRIF, TRAM and SARM) in gingival epithelial cells and endothelial cells. It was observed that P. gingivalis is able to modulate the signaling cascades activated through its recognition by TLR4/2 in gingival epithelial cells and endothelial cells. Indeed, MAL-MyD88 protein-protein interactions associated with TLR4 was the main pathway activated by P. gingivalis infection. When transient siRNA inhibition was performed, cell viability, inflammation, and cell death induced by infection decreased and such deleterious effects were almost absent when MAL or TRAM were targeted. This study emphasizes the role of such TIR adapter proteins in P. gingivalis elicited inflammation and the precise evaluation of TIR adapter protein interactions may pave the way for future therapeutics in both periodontitis and systemic disease with a P. gingivalis involvement, such as atherothrombosis.
Collapse
Affiliation(s)
- Isaac M Bugueno
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.,Faculté de Chirurgie Dentaire, Université de Strasbourg, France.,Pôle de Médecine et de Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, France
| |
Collapse
|
13
|
Stutz C, Clauss F, Huck O, Schulz G, Benkirane-Jessel N, Bornert F, Kuchler-Bopp S, Strub M. Eruption of Bioengineered Teeth: A New Approach Based on a Polycaprolactone Biomembrane. Nanomaterials (Basel) 2021; 11:nano11051315. [PMID: 34067681 PMCID: PMC8156264 DOI: 10.3390/nano11051315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 05/02/2021] [Accepted: 05/10/2021] [Indexed: 12/27/2022]
Abstract
Obtaining a functional tooth is the ultimate goal of tooth engineering. However, the implantation of bioengineered teeth in the jawbone of adult animals never allows for spontaneous eruption due mainly to ankylosis within the bone crypt. The objective of this study was to develop an innovative approach allowing eruption of implanted bioengineered teeth through the isolation of the germ from the bone crypt using a polycaprolactone membrane (PCL). The germs of the first lower molars were harvested on the 14th day of embryonic development, cultured in vitro, and then implanted in the recipient site drilled in the maxillary bone of adult mice. To prevent the ankylosis of the dental germ, a PCL membrane synthesized by electrospinning was placed between the germ and the bone. After 10 weeks of follow-up, microtomography, and histology of the implantation site were performed. In control mice where germs were directly placed in contact with the bone, a spontaneous eruption of bioengineered teeth was only observed in 3.3% of the cases versus 19.2% in the test group where PCL biomembrane was used as a barrier (p < 0.1). This preliminary study is the first to describe an innovative method allowing the eruption of bioengineered tooth implanted directly in the jawbone of mice. This new approach is a hope for the field of tooth regeneration, especially in children with oligodontia in whom titanium implants are not an optimal solution.
Collapse
Affiliation(s)
- Céline Stutz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
| | - François Clauss
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
- Department of Pediatric Dentistry, University Hospitals of Strasbourg (HUS), 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
- Department of Periodontology, University Hospitals of Strasbourg (HUS), 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Georg Schulz
- Core Facility Micro- and Nanotomography, Biomaterials Science Center (BMC), Department of Biomedical Engineering, University of Basel, Gewerbestrasse 14, 4123 Allschwil, Switzerland;
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
| | - Fabien Bornert
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
- Department of Pediatric Dentistry, University Hospitals of Strasbourg (HUS), 1 Place de l’Hôpital, 67000 Strasbourg, France
- Department of Oral Medicine and Oral Surgery, University Hospitals of Strasbourg (HUS), 1 Place de l’Hôpital, 67000 Strasbourg, France
| | - Sabine Kuchler-Bopp
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
| | - Marion Strub
- INSERM (French National Institute of Health and Medical Research), UMR 1260, CRBS Regenerative NanoMedicine (RNM), FMTS, 1 rue Eugène Boeckel, 67084 Strasbourg, France; (C.S.); (F.C.); (O.H.); (N.B.-J.); (F.B.); (S.K.-B.)
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
- Department of Pediatric Dentistry, University Hospitals of Strasbourg (HUS), 1 Place de l’Hôpital, 67000 Strasbourg, France
- Correspondence:
| |
Collapse
|
14
|
Batool F, Özçelik H, Stutz C, Gegout PY, Benkirane-Jessel N, Petit C, Huck O. Modulation of immune-inflammatory responses through surface modifications of biomaterials to promote bone healing and regeneration. J Tissue Eng 2021; 12:20417314211041428. [PMID: 34721831 PMCID: PMC8554547 DOI: 10.1177/20417314211041428] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Accepted: 08/06/2021] [Indexed: 12/25/2022] Open
Abstract
Control of inflammation is indispensable for optimal oral wound healing and tissue regeneration. Several biomaterials have been used to enhance the regenerative outcomes; however, the biomaterial implantation can ensure an immune-inflammatory response. The interface between the cells and the biomaterial surface plays a critical role in determining the success of soft and hard tissue regeneration. The initial inflammatory response upon biomaterial implantation helps in tissue repair and regeneration, however, persistant inflammation impairs the wound healing response. The cells interact with the biomaterials through extracellular matrix proteins leading to protein adsorption followed by recruitment, attachment, migration, and proliferation of several immune-inflammatory cells. Physical nanotopography of biomaterials, such as surface proteins, roughness, and porosity, is crucial for driving cellular attachment and migration. Similarly, modification of scaffold surface chemistry by adapting hydrophilicity, surface charge, surface coatings, can down-regulate the initiation of pro-inflammatory cascades. Besides, functionalization of scaffold surfaces with active biological molecules can down-regulate pro-inflammatory and pro-resorptive mediators' release as well as actively up-regulate anti-inflammatory markers. This review encompasses various strategies for the optimization of physical, chemical, and biological properties of biomaterial and the underlying mechanisms to modulate the immune-inflammatory response, thereby, promoting the tissue integration and subsequent soft and hard tissue regeneration potential of the administered biomaterial.
Collapse
Affiliation(s)
- Fareeha Batool
- Faculté de Chirurgie-dentaire, Université de Strasbourg, Strasbourg, France
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Hayriye Özçelik
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Céline Stutz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Pierre-Yves Gegout
- Faculté de Chirurgie-dentaire, Université de Strasbourg, Strasbourg, France
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Pôle de médecine et chirurgie bucco-dentaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Catherine Petit
- Faculté de Chirurgie-dentaire, Université de Strasbourg, Strasbourg, France
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Pôle de médecine et chirurgie bucco-dentaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Olivier Huck
- Faculté de Chirurgie-dentaire, Université de Strasbourg, Strasbourg, France
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Pôle de médecine et chirurgie bucco-dentaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| |
Collapse
|
15
|
Hua G, Bergon A, Cauchy P, Kahn-Perlès B, Bertucci F, Birnbaum D, Benkirane-Jessel N, Imbert J. ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer. J Cell Biochem 2020; 121:4870-4886. [PMID: 32628295 DOI: 10.1002/jcb.29762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Accepted: 05/05/2020] [Indexed: 11/10/2022]
Abstract
The presence of nuclear ERBB2 receptor-type tyrosine kinase is one of the causes of the resistance to membrane ERBB2-targeted therapy in breast cancers. It has been previously reported that this nuclear location arises through at least two different mechanisms: proteolytic shedding of the extracellular domain of the full-length receptor and translation of the messenger RNA (mRNA)-encoding ERBB2 from internal initiation codons. Here, we report a new mechanism and function where a significant portion of nuclear ERBB2 results from the translation of the variant ERBB2 mRNA under the transcriptional control of a distal promoter that is actively used in breast cancer cells. We show that both membrane ERBB2a and nuclear ERBB2b isoforms are prevalently expressed in breast cancer cell lines and carcinoma samples. The ERBB2b isoform, which is translated from mRNA variant 2, can directly translocate into the nucleus due to the lack of the signal peptide which is required for an intermediate membrane location. Small interfering RNA-mediated gene silencing showed that ERBB2b can repress ERBB2a expression, encoded by variant 1, whereas ERBB2a activates ERBB2b. Nuclear ERBB2 binding to its own promoter was revealed by chromatin immunoprecipitation assay. Altogether, our results provide new insights into the origin and function of nuclear ERBB2 where it can participate at the same time in a positive or a negative feedback autoregulatory loop, dependent on which of its promoters this bona fide transcription factor is acting. They also provide a new understanding for the resistance to therapies targeting the membrane-anchored ERBB2 in breast cancer.
Collapse
Affiliation(s)
- Guoqiang Hua
- INSERM UMR1090 TAGC, Aix-Marseille University, Marseille, France
- INSERM UMR1260, RNM, FMTS, Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Aurélie Bergon
- INSERM UMR1090 TAGC, Aix-Marseille University, Marseille, France
| | - Pierre Cauchy
- INSERM UMR1090 TAGC, Aix-Marseille University, Marseille, France
- Max Planck Institute of Immunobiology and Epigenetics, Freiburg im Breisgau, Germany
| | | | - François Bertucci
- Laboratoire d'Oncologie Prédictive, CRCM, CNRS UMR 7258, INSERM U1068, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France
| | - Daniel Birnbaum
- Laboratoire d'Oncologie Prédictive, CRCM, CNRS UMR 7258, INSERM U1068, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France
| | - Nadia Benkirane-Jessel
- INSERM UMR1260, RNM, FMTS, Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Jean Imbert
- INSERM UMR1090 TAGC, Aix-Marseille University, Marseille, France
| |
Collapse
|
16
|
Stutz C, Batool F, Petit C, Strub M, Kuchler-Bopp S, Benkirane-Jessel N, Huck O. Influence of parathyroid hormone on periodontal healing in animal models: A systematic review. Arch Oral Biol 2020; 120:104932. [PMID: 33113458 DOI: 10.1016/j.archoralbio.2020.104932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 07/10/2020] [Accepted: 09/21/2020] [Indexed: 12/09/2022]
Abstract
OBJECTIVES The purpose of this systematic review was to determine the potential interest of parathyroid hormone (PTH) as an adjunct to periodontal treatment based on studies performed in rodents. MATERIALS & METHODS Electronic databases (MEDLINE, Web of Science) were searched up to December 2019. Studies assessing the impact of PTH administration in experimental periodontitis in rodents have been identified. RESULTS Amongst the 247 identified articles, 10 met the inclusion criteria and were included in this systematic review. Experimental periodontitis was mainly induced by ligature placement or surgically with a dental bur. All studies considered bone healing after PTH administration at different frequencies as primary outcome. Results showed that an intermittent administration of PTH promoted bone healing and neovascularization. Nevertheless, a decrease of soft tissue inflammation was also observed. CONCLUSION Intermittent administration of PTH appears to enhance significantly periodontal healing and to promote alveolar bone regeneration. However, due to the risk of side effects, the development of scaffolds allowing its local and time-controlled delivery is of importance.
Collapse
Affiliation(s)
- Céline Stutz
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Fareeha Batool
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Catherine Petit
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France; Pôle de Médecine et de Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Marion Strub
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France; Pôle de Médecine et de Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Sabine Kuchler-Bopp
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Olivier Huck
- INSERM, UMR 1260 'Osteoarticular and Dental Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France; Pôle de Médecine et de Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
| |
Collapse
|
17
|
Hassan S, Peluso J, Chalhoub S, Idoux Gillet Y, Benkirane-Jessel N, Rochel N, Fuhrmann G, Ubeaud-Sequier G. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1. PLoS One 2020; 15:e0240676. [PMID: 33052979 PMCID: PMC7556446 DOI: 10.1371/journal.pone.0240676] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 09/30/2020] [Indexed: 12/18/2022] Open
Abstract
The impact of cancer on lifespan is significantly increasing worldwide. Enhanced activity of drug efflux pumps and the incidences of the tumor microenvironment such as the apparition of a hypoxic gradient inside of the bulk tumor, are the major causes of chemotherapy failure. For instance, expression of Hypoxia-inducible factor (HIF-1α) has been associated with metastasis, resistance to chemotherapy and reduced survival rate. One of the current challenges to fight against cancer is therefore to find new molecules with therapeutic potential that could overcome this chemoresistance. In the present study, we focused on the bioactive plant flavonoid quercetin, which has strong antioxidant and anti-proliferative properties. We examined the efficacy of combined treatments of quercetin and the anti-cancer drugs gemcitabine and doxorubicin, known to specifically act on human pancreatic and hepatic cancer cells, respectively. Moreover, our study aimed to investigate more in-depth the implication of the multidrug transporter MDR1 and HIF-1α n chemoresistance and if quercetin could act on the activity of the drug efflux pumps and the hypoxia-associated effects. We observed that the anti-cancer drugs, were more effective when administered in combination with quercetin, as shown by an increased percentage of dead cells up to 60% in both 2D and 3D cultures. In addition, our results indicated that the combination of anti-cancer drugs and quercetin down-regulated the expression of HIF-1α and increased the expression levels of the regulator of apoptosis p53. Moreover, we observed that quercetin could inhibit the efflux activity of MDR1. Finally, our in vitro study suggests that the efficiency of the chemotherapeutic activity of known anti-cancer drugs might be significantly increased upon combination with quercetin. This flavonoid may therefore be a promising pharmacological agent for novel combination therapy since it potentializes the cytotoxic activity of gemcitabine and doxorubicin on by targeting the chemoresistance developed by the pancreatic and liver cancer cells respectively.
Collapse
Affiliation(s)
- Sarah Hassan
- Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France
- Platform eBiocyt-UPS1401, Faculty of Pharmacy, University of Strasbourg, Strasbourg, France
- * E-mail:
| | - Jean Peluso
- Platform eBiocyt-UPS1401, Faculty of Pharmacy, University of Strasbourg, Strasbourg, France
| | - Sandra Chalhoub
- Department of Integrative Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM, U964 CNRS UMR 7104, Université de Strasbourg, Strasbourg, France
| | - Ysia Idoux Gillet
- Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France
| | - Nadia Benkirane-Jessel
- Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France
| | - Natacha Rochel
- Department of Integrative Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM, U964 CNRS UMR 7104, Université de Strasbourg, Strasbourg, France
| | - Guy Fuhrmann
- Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France
| | - Genevieve Ubeaud-Sequier
- Regenerative Nanomedicine, INSERM UMR 1260, FMTS, University of Strasbourg, Strasbourg, France
- Platform eBiocyt-UPS1401, Faculty of Pharmacy, University of Strasbourg, Strasbourg, France
- Department of Pharmacy, Strasbourg University Hospital, Strasbourg, France
| |
Collapse
|
18
|
Nebigil CG, Moog C, Vagner S, Benkirane-Jessel N, Smith DR, Désaubry L. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses. Eur J Med Chem 2020; 203:112653. [PMID: 32693294 PMCID: PMC7362831 DOI: 10.1016/j.ejmech.2020.112653] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/06/2020] [Accepted: 07/07/2020] [Indexed: 12/19/2022]
Abstract
Flavaglines are cyclopenta[b]benzofurans found in plants of the genus Aglaia, several species of which are used in traditional Chinese medicine. These compounds target the initiation factor of translation eIF4A and the scaffold proteins prohibitins-1 and 2 (PHB1/2) to exert various pharmacological activities, including antiviral effects against several types of viruses, including coronaviruses. This review is focused on the antiviral effects of flavaglines and their therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Collapse
Affiliation(s)
- Canan G Nebigil
- INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
| | - Christiane Moog
- INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France
| | - Stéphan Vagner
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France; Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay, France
| | - Nadia Benkirane-Jessel
- INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg, France
| | - Duncan R Smith
- Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand
| | - Laurent Désaubry
- INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.
| |
Collapse
|
19
|
Stutz C, Strub M, Clauss F, Huck O, Schulz G, Gegout H, Benkirane-Jessel N, Bornert F, Kuchler-Bopp S. A New Polycaprolactone-Based Biomembrane Functionalized with BMP-2 and Stem Cells Improves Maxillary Bone Regeneration. Nanomaterials (Basel) 2020; 10:nano10091774. [PMID: 32911737 PMCID: PMC7558050 DOI: 10.3390/nano10091774] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 09/05/2020] [Accepted: 09/06/2020] [Indexed: 12/12/2022]
Abstract
Oral diseases have an impact on the general condition and quality of life of patients. After a dento-alveolar trauma, a tooth extraction, or, in the case of some genetic skeletal diseases, a maxillary bone defect, can be observed, leading to the impossibility of placing a dental implant for the restoration of masticatory function. Recently, bone neoformation was demonstrated after in vivo implantation of polycaprolactone (PCL) biomembranes functionalized with bone morphogenic protein 2 (BMP-2) and ibuprofen in a mouse maxillary bone lesion. In the present study, human bone marrow derived mesenchymal stem cells (hBM-MSCs) were added on BMP-2 functionalized PCL biomembranes and implanted in a maxillary bone lesion. Viability of hBM-MSCs on the biomembranes has been observed using the "LIVE/DEAD" viability test and scanning electron microscopy (SEM). Maxillary bone regeneration was observed for periods ranging from 90 to 150 days after implantation. Various imaging methods (histology, micro-CT) have demonstrated bone remodeling and filling of the lesion by neoformed bone tissue. The presence of mesenchymal stem cells and BMP-2 allows the acceleration of the bone remodeling process. These results are encouraging for the effectiveness and the clinical use of this new technology combining growth factors and mesenchymal stem cells derived from bone marrow in a bioresorbable membrane.
Collapse
Affiliation(s)
- Céline Stutz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
| | - Marion Strub
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Faculté de Chirurgie Dentaire, Université de Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
- Pôle de Médecine et Chirurgie Bucco-Dentaires, Pediatric Dentistry, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l’Hôpital, 67000 Strasbourg, France
| | - François Clauss
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Faculté de Chirurgie Dentaire, Université de Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
- Pôle de Médecine et Chirurgie Bucco-Dentaires, Pediatric Dentistry, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l’Hôpital, 67000 Strasbourg, France
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Faculté de Chirurgie Dentaire, Université de Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
- Pôle de Médecine et Chirurgie Bucco-Dentaires, Periodontology, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l’Hôpital, 67000 Strasbourg, France
| | - Georg Schulz
- Core Facility Micro- and Nanotomography, Biomaterials Science Center (BMC), Department of Biomedical Engineering, University of Basel, Gewerbestrasse 14, 4123 Allschwil, Switzerland;
| | - Hervé Gegout
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Faculté de Chirurgie Dentaire, Université de Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Faculté de Chirurgie Dentaire, Université de Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France
| | - Fabien Bornert
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Pôle de Médecine et Chirurgie Bucco-Dentaires, Pediatric Dentistry, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l’Hôpital, 67000 Strasbourg, France
- Pôle de Médecine et Chirurgie Bucco-Dentaires, Oral Medicine and Oral Surgery, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l’Hôpital, 67000 Strasbourg, France
| | - Sabine Kuchler-Bopp
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France; (C.S.); (M.S.); (F.C.); (O.H.); (H.G.); (N.B.-J.); (F.B.)
- Correspondence: ; Tel.: +33-619610523
| |
Collapse
|
20
|
Harmouch E, Seitlinger J, Chaddad H, Ubeaud-Sequier G, Barths J, Saidu S, Désaubry L, Grandemange S, Massfelder T, Fuhrmann G, Fioretti F, Dontenwill M, Benkirane-Jessel N, Idoux-Gillet Y. Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes. Sci Rep 2020; 10:13750. [PMID: 32792639 PMCID: PMC7426813 DOI: 10.1038/s41598-020-70820-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Accepted: 07/30/2020] [Indexed: 11/13/2022] Open
Abstract
Glioblastoma (GBM) is one of the most aggressive types of cancer, which begins within the brain. It is the most invasive type of glioma developed from astrocytes. Until today, Temozolomide (TMZ) is the only standard chemotherapy for patients with GBM. Even though chemotherapy extends the survival of patients, there are many undesirable side effects, and most cases show resistance to TMZ. FL3 is a synthetic flavagline which displays potent anticancer activities, and is known to inhibit cell proliferation, by provoking cell cycle arrest, and leads to apoptosis in a lot of cancer cell lines. However, the effect of FL3 in glioblastoma cancer cells has not yet been examined. Hypoxia is a major problem for patients with GBM, resulting in tumor resistance and aggressiveness. In this study, we explore the effect of FL3 in glioblastoma cells under normoxia and hypoxia conditions. Our results clearly indicate that this synthetic flavagline inhibits cell proliferation and induced senescence in glioblastoma cells cultured under both conditions. In addition, FL3 treatment had no effect on human brain astrocytes. These findings support the notion that the FL3 molecule could be used in combination with other chemotherapeutic agents or other therapies in glioblastoma treatments.
Collapse
Affiliation(s)
- Ezeddine Harmouch
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
| | - Joseph Seitlinger
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
- Hôpitaux Universitaire de Strasbourg (HUS), 67000, Strasbourg, France
| | - Hassan Chaddad
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
| | - Geneviève Ubeaud-Sequier
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
| | - Jochen Barths
- Core Facility for Flow Cytometry, Cell Sorting and EliSpot, UMR 1110, INSERM, Strasbourg, France
| | - Sani Saidu
- CNRS UMR 7021, Laboratoire de Bioimagerie et Pathologies, Faculté de Pharmacie, Strasbourg, France
| | - Laurent Désaubry
- Laboratory of Cardio-Oncology and Medicinal Chemistry (FRE 2033), CNRS, Institut Le Bel, Strasbourg, France
- Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
| | - Stéphanie Grandemange
- CNRS, UMR 7039 CRAN, Université de Lorraine, Campus Sciences, 30 bvd des Aiguillettes, 54505, Vandoeuvre les Nancy Cedex, France
| | - Thierry Massfelder
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
| | - Guy Fuhrmann
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
| | - Florence Fioretti
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France
- Hôpitaux Universitaire de Strasbourg (HUS), 67000, Strasbourg, France
| | - Monique Dontenwill
- CNRS UMR 7021, Laboratoire de Bioimagerie et Pathologies, Faculté de Pharmacie, Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France.
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 67000, Strasbourg, France.
| |
Collapse
|
21
|
Favreau H, Pijnenburg L, Seitlinger J, Fioretti F, Keller L, Scipioni D, Adriaensen H, Kuchler-Bopp S, Ehlinger M, Mainard D, Rosset P, Hua G, Gentile L, Benkirane-Jessel N. Osteochondral repair combining therapeutics implant with mesenchymal stem cells spheroids. Nanomedicine 2020; 29:102253. [PMID: 32619705 DOI: 10.1016/j.nano.2020.102253] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 06/05/2020] [Accepted: 06/19/2020] [Indexed: 12/21/2022]
Abstract
Functional articular cartilage regeneration remains challenging, and it is essential to restore focal osteochondral defects and prevent secondary osteoarthritis. Combining autologous stem cells with therapeutic medical device, we developed a bi-compartmented implant that could promote both articular cartilage and subchondral bone regeneration. The first compartment based on therapeutic collagen associated with bone morphogenetic protein 2, provides structural support and promotes subchondral bone regeneration. The second compartment contains bone marrow-derived mesenchymal stem cell spheroids to support the regeneration of the articular cartilage. Six-month post-implantation, the regenerated articular cartilage surface was 3 times larger than that of untreated animals, and the regeneration of the osteochondral tissue occurred during the formation of hyaline-like cartilage. Our results demonstrate the positive impact of this combined advanced therapy medicinal product, meeting the needs of promising osteochondral regeneration in critical size articular defects in a large animal model combining not only therapeutic implant but also stem cells.
Collapse
Affiliation(s)
- Henri Favreau
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Hôpitaux universitaires de Strasbourg (HUS), Hôpital de Hautepierre, Service de rhumatologie, Service de chirurgie thoracique and Service de chirurgie orthopédique et de traumatologie, Université de Strasbourg, Strasbourg, France
| | - Luc Pijnenburg
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Hôpitaux universitaires de Strasbourg (HUS), Hôpital de Hautepierre, Service de rhumatologie, Service de chirurgie thoracique and Service de chirurgie orthopédique et de traumatologie, Université de Strasbourg, Strasbourg, France
| | - Joseph Seitlinger
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Hôpitaux universitaires de Strasbourg (HUS), Hôpital de Hautepierre, Service de rhumatologie, Service de chirurgie thoracique and Service de chirurgie orthopédique et de traumatologie, Université de Strasbourg, Strasbourg, France
| | - Florence Fioretti
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Strasbourg, France
| | - Laetitia Keller
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Strasbourg, France
| | - Dominique Scipioni
- Hôpital Erasme-Cliniques universitaires de Bruxelles, Université libre de Bruxelles (ULB), CHIREC-Hôpital Delta, Belgique
| | - Hans Adriaensen
- CHRU de Tours, Service de Chirurgie Orthopédique 2, Faculté de Médecine de Tours, and INRA de tours, Université François Rabelais, Tours, France
| | - Sabine Kuchler-Bopp
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
| | - Matthieu Ehlinger
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Hôpitaux universitaires de Strasbourg (HUS), Hôpital de Hautepierre, Service de rhumatologie, Service de chirurgie thoracique and Service de chirurgie orthopédique et de traumatologie, Université de Strasbourg, Strasbourg, France
| | - Didier Mainard
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Hôpital central Nancy, Service d'Orthopédie, Nancy, France
| | - Phillippe Rosset
- CHRU de Tours, Service de Chirurgie Orthopédique 2, Faculté de Médecine de Tours, and INRA de tours, Université François Rabelais, Tours, France
| | - Guoqiang Hua
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Strasbourg, France
| | - Luca Gentile
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Strasbourg, France.
| |
Collapse
|
22
|
Petit C, Batool F, Stutz C, Anton N, Klymchenko A, Vandamme T, Benkirane-Jessel N, Huck O. Development of a thermosensitive statin loaded chitosan-based hydrogel promoting bone healing. Int J Pharm 2020; 586:119534. [PMID: 32531451 DOI: 10.1016/j.ijpharm.2020.119534] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 06/05/2020] [Accepted: 06/06/2020] [Indexed: 01/04/2023]
Abstract
Statins have been proposed as potential adjuvant to periodontal treatment due to their pleiotropic properties. A new thermosensitive chitosan hydrogel loaded with statins (atorvastatin and lovastatin) nanoemulsions was synthesized to allow a spatially controlled local administration of active compounds at lesion site. Spontaneous nano-emulsification method was used to synthesize statins loaded nanoemulsions. In vitro, atorvastatin and lovastatin loaded nanoemulsions were cytocompatible and were able to be uptake by oral epithelial cells. Treatment of Porphyromonas gingivalis infected oral epithelial cells and gingival fibroblasts with atorvastatin and lovastatin loaded nanoemulsions decreased significantly pro-inflammatory markers expression (TNF-α and IL-1β) and pro-osteoclastic RANKL. Nevertheless, such treatment induced the expression of Bone sialoprotein 2 (BSP2) in osteoblast emphasizing the pro-healing properties of atorvastatin and lovastatin nanoemulsions. In vivo, in a calvarial bone defect model (2 mm), treatment with the hydrogel loaded with atorvastatin and lovastatin nanoemulsions induced a significant increase of the neobone formation in comparison with systemic administration of statins. This study demonstrates the potential of this statins loaded hydrogel to improve bone regeneration and to decrease soft tissue inflammation. Its use in the specific context of periodontitis management could be considered in the future with a reduced risk of side effects.
Collapse
Affiliation(s)
- Catherine Petit
- INSERM, UMR 1260 'Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France; Pôle de Médecine et de Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Fareeha Batool
- INSERM, UMR 1260 'Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France
| | - Céline Stutz
- INSERM, UMR 1260 'Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Nicolas Anton
- Université de Strasbourg, CNRS, CAMB UMR 7199, Strasbourg, France
| | - Andrey Klymchenko
- Université de Strasbourg, CNRS, LBP UMR 7021, F-67000 Strasbourg, France
| | - Thierry Vandamme
- Université de Strasbourg, CNRS, CAMB UMR 7199, Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM, UMR 1260 'Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Olivier Huck
- INSERM, UMR 1260 'Regenerative Nanomedicine', Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France; Pôle de Médecine et de Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
| |
Collapse
|
23
|
Voisin C, Cauchois G, Reppel L, Laroye C, Louarn L, Schenowitz C, Sonon P, Poras I, Wang V, D. Carosella E, Benkirane-Jessel N, Moreau P, Rouas-Freiss N, Bensoussan D, Huselstein C. Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation? J Clin Med 2020; 9:jcm9020423. [PMID: 32033151 PMCID: PMC7073626 DOI: 10.3390/jcm9020423] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 01/24/2020] [Accepted: 01/28/2020] [Indexed: 01/13/2023] Open
Abstract
Background: Umbilical mesenchymal stem/stromal cells (MSCs), and especially those derived from Wharton’s jelly (WJ), are a promising engineering tool for tissue repair in an allogeneic context. This is due to their differentiation capacity and immunological properties, like their immunomodulatory potential and paracrine activity. Hence, these cells may be considered an Advanced Therapy Medicinal Product (ATMP). The purpose of this work was to differentiate MSCs from WJ (WJ-MSCs) into chondrocytes using a scaffold and to evaluate, in vitro, the immunomodulatory capacities of WJ-MSCs in an allogeneic and inflammatory context, mimicked by IFN-γ and TNF-α priming during the chondrogenic differentiation. Methods: Scaffolds were made from hydrogel composed by alginate enriched in hyaluronic acid (Alg/HA). Chondrogenic differentiation, immunological function, phenotype expression, but also secreted soluble factors were the different parameters followed during 28 days of culture. Results: During chondrocyte differentiation, even in an allogeneic context, WJ-MSCs remained unable to establish the immunological synapse or to induce T cell alloproliferation. Moreover, interestingly, paracrine activity and functional immunomodulation were maintained during cell differentiation. Conclusion: These results show that WJ-MSCs remained hypoimmunogenic and retained immunomodulatory properties even when they had undergone chondrocyte differentiation.
Collapse
Affiliation(s)
- Charlotte Voisin
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
- Correspondence: ; Tel.: +33-372-74-6585
| | - Ghislaine Cauchois
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
| | - Loïc Reppel
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
- CHRU de Nancy, Unité de Thérapie Cellulaire Banque de Tissus, 54500 Vandœuvre-lès-Nancy, France
| | - Caroline Laroye
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
- CHRU de Nancy, Unité de Thérapie Cellulaire Banque de Tissus, 54500 Vandœuvre-lès-Nancy, France
| | - Laetitia Louarn
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Chantal Schenowitz
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Paulin Sonon
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Isabelle Poras
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Valentine Wang
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
| | - Edgardo D. Carosella
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Nadia Benkirane-Jessel
- INSERM-UNISTRA UMR1260, Regenerative Nanomedicine laboratory, Faculté de Médecine, FMTS, Strasbourg CEDEX F-67085, France;
| | - Philippe Moreau
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Nathalie Rouas-Freiss
- CEA, DRF-Institut François Jacob, Service de Recherches en Hémato-Immunologie, Hopital Saint-Louis, 75010 Paris, France; (L.L.); (C.S.); (P.S.); (I.P.); (E.D.C.); (P.M.); (N.R.-F.)
- Université de Paris, CEA, U976 HIPI Unit (Human Immunology, Physiopathology, Immunotherapy), Institut de Recherche Saint-Louis, 75010 Paris, France
| | - Danièle Bensoussan
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- CHRU de Nancy, Unité de Thérapie Cellulaire Banque de Tissus, 54500 Vandœuvre-lès-Nancy, France
| | - Céline Huselstein
- UMR 7365 CNRS-Université de Lorraine, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle de l’Université de Lorraine, Campus brabois-santé, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, 54500 Vandoeuvre-lès-nancy, France; (G.C.); (L.R.); (C.L.); (V.W.); (D.B.); (C.H.)
- UMS2008 IBSLor, Campus brabois-santé, 9 Avenue de la Forêt de Haye, BP20199, 54500 Vandoeuvre-lès-nancy, France
| |
Collapse
|
24
|
Batool F, Agossa K, Lizambard M, Petit C, Bugueno IM, Delcourt-Debruyne E, Benkirane-Jessel N, Tenenbaum H, Siepmann J, Siepmann F, Huck O. In-situ forming implants loaded with chlorhexidine and ibuprofen for periodontal treatment: Proof of concept study in vivo. Int J Pharm 2019; 569:118564. [PMID: 31352049 DOI: 10.1016/j.ijpharm.2019.118564] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 07/23/2019] [Accepted: 07/24/2019] [Indexed: 12/12/2022]
Abstract
Control of infection and inflammation is crucial for the success of periodontal treatment. In this study, in-situ forming implants (ISFI) loaded with chlorhexidine dihydrochloride (CHX) and ibuprofen (IBU) were developed and tested to optimize periodontal treatment outcomes. Release profiles were promising. Exposure to 1.5% and 5.3% CHX-IBU loaded ISFI's release media decreased significantly the P. gingivalis growth up to 20-fold and 35-fold, respectively, after 48 h (p < 0.05). The metabolic activity assay of gingival epithelial cells (EC) demonstrated 1.5% CHX-IBU-loaded ISFI to be non-toxic, therefore, it was selected for further experimentation. Furthermore, significant down-regulation of TNF-α release (34% at 6 h and 43% at 24 h, p < 0.05) in P. gingivalis lipopolysaccharide (Pg-LPS) stimulated EC exposed to 1.5% CHX-IBU ISFI release medium was demonstrated by ELISA. In vivo, 1.5% CHX-IBU ISFI was injected into the periodontal pocket in an experimental periodontitis mouse model and the reduction in inflammation and improvement in periodontal wound healing was evaluated through inflammatory cell scoring and histomorphometry at 7- and 15-days post-treatment. The results indicate that CHX-IBU loaded ISFI could be efficient as adjuvant to periodontal therapy for the control of infection and inflammation. Moreover, other (e.g., pro-regenerative) drugs could be incorporated into ISFI to further improve periodontal treatment outcomes.
Collapse
Affiliation(s)
- Fareeha Batool
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France
| | - Kevimy Agossa
- Univ. Lille, Inserm, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, F-59000 Lille, France
| | - Martin Lizambard
- Univ. Lille, Inserm, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, F-59000 Lille, France
| | - Catherine Petit
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France
| | - Isaac Maximiliano Bugueno
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France
| | - Elisabeth Delcourt-Debruyne
- Univ. Lille, Inserm, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, F-59000 Lille, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Henri Tenenbaum
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France
| | - Juergen Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, F-59000 Lille, France
| | - Florence Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, F-59000 Lille, France
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France.
| |
Collapse
|
25
|
Zein N, Harmouch E, Lutz JC, Fernandez De Grado G, Kuchler-Bopp S, Clauss F, Offner D, Hua G, Benkirane-Jessel N, Fioretti F. Polymer-Based Instructive Scaffolds for Endodontic Regeneration. Materials (Basel) 2019; 12:ma12152347. [PMID: 31344822 PMCID: PMC6695966 DOI: 10.3390/ma12152347] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 07/19/2019] [Accepted: 07/22/2019] [Indexed: 12/22/2022]
Abstract
The challenge of endodontic regeneration is modulated by clinical conditions which determine five kinds of tissue requirements: pulp connective-tissue formation, dentin formation, revascularization, reinnervation and radicular edification. Polymer scaffolds constitute keystone of the different endodontic regenerative strategies. Indeed, scaffolds are crucial for carrying active molecules and competent cells which optimize the regeneration. Hydrogels are very beneficial for controlling viscosity and porosity of endodontic scaffolds. The nanofibrous and microporous scaffolds mimicking extracellular matrix are also of great interest for promoting dentin-pulp formation. Two main types of polymer scaffolds are highlighted: collagen and fibrin. Collagen scaffolds which are similar to native pulp tissue, are adequate for pulp connective tissue formation. Functionnalization by active biomolecules as BMP, SDF-1, G-CSF enhances their properties. Fibrin or PRF scaffolds present the advantage of promoting stem cell differentiation and concomitant revascularisation. The choice of the type of polymers (polypeptide, PCL, chitosan) can depend on its ability to deliver the active biomolecule or to build as suitable hydrogel as possible. Since 2010s, proposals to associate different types of polymers in a same scaffold have emerged for adding advantages or for offsetting a disadvantage of a polymer. Further works would study the synergetic effects of different innovative polymers composition.
Collapse
Affiliation(s)
- Naimah Zein
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
| | - Ezeddine Harmouch
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
| | - Jean-Christophe Lutz
- Faculté de Médecine de Strasbourg, Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
- Pôle de Chirurgie Maxillo-Faciale et Stomatologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
| | - Gabriel Fernandez De Grado
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
- Hôpitaux Universitaires de Strasbourg, Pôle de Médecine et Chirurgie Bucco-Dentaires, 67000 Strasbourg, France
| | - Sabine Kuchler-Bopp
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
| | - François Clauss
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
- Hôpitaux Universitaires de Strasbourg, Pôle de Médecine et Chirurgie Bucco-Dentaires, 67000 Strasbourg, France
| | - Damien Offner
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
- Hôpitaux Universitaires de Strasbourg, Pôle de Médecine et Chirurgie Bucco-Dentaires, 67000 Strasbourg, France
| | - Guoqiang Hua
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
| | - Florence Fioretti
- French National Institute of Health and Medical Research (INSERM), Regenerative Nanomedicine, UMR 1260, FMTS, 67085 Strasbourg, France.
- Faculté de Chirurgie Dentaire de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France.
- Hôpitaux Universitaires de Strasbourg, Pôle de Médecine et Chirurgie Bucco-Dentaires, 67000 Strasbourg, France.
| |
Collapse
|
26
|
Offner D, de Grado GF, Meisels I, Pijnenburg L, Fioretti F, Benkirane-Jessel N, Musset AM. Bone Grafts, Bone Substitutes and Regenerative Medicine Acceptance for the Management of Bone Defects Among French Population: Issues about Ethics, Religion or Fear? Cell Med 2019; 11:2155179019857661. [PMID: 32634194 PMCID: PMC6587382 DOI: 10.1177/2155179019857661] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Accepted: 05/21/2019] [Indexed: 12/13/2022]
Abstract
Several techniques exist to manage bone defects in patients: bone grafts (autograft, allograft, xenograft), use of synthetic bone substitutes, or use of the products of bone regenerative medicine. Studies generally focus on their efficacy, but few focus on their acceptance. Our objectives were to assess their theoretical acceptance among the French general population, and to identify issues justifying refusals, by mean of an open e-questionnaire. The questionnaire was submitted to a general French population, and explained these techniques in an understandable way. Participants were asked to say whether they would accept or refuse these techniques, specifying why in case of refusal (fear of the technique, ethical reasons, religious reasons). In total, 562 persons participated. Autograft and use of the products of bone regenerative medicine were the most accepted techniques (93.4% and 94.1%, respectively). Xenograft was the least accepted technique (58.2%). Most refusals were due to fear such as failure, pain, infection (autograft 8%, allograft 14.9%, xenograft 25.3%, synthetic bone substitutes 14.6%, and products of bone regenerative medicine 6.8%). Ethical reasons were mostly mentioned for allograft (6.4%) and xenograft (18.3%). Religious reasons were scarcely mentioned, only for xenograft (1.2%). Thus, acceptance of techniques does not seem to be greatly linked to sociodemographic characteristics in France. However, other countries with their own cultural, religious, and population patterns may show different levels of acceptance. This study shows that bone regenerative medicine is a promising research direction, reaching biological and also humanist quality standards, expected to improve the health of patients. Information is still the cornerstone to defuse issues about fear.
Collapse
Affiliation(s)
- Damien Offner
- INSERM (French National Institute of Health and Medical Research), UMR1260, Regenerative Nanomedicine (RNM), FMTS.,Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg.,Hôpitaux Universitaires de Strasbourg, Strasbourg.,Both the authors contributed equally to this article
| | - Gabriel Fernandez de Grado
- INSERM (French National Institute of Health and Medical Research), UMR1260, Regenerative Nanomedicine (RNM), FMTS.,Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg.,Hôpitaux Universitaires de Strasbourg, Strasbourg.,Both the authors contributed equally to this article
| | - Inès Meisels
- Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg.,Hôpitaux Universitaires de Strasbourg, Strasbourg
| | - Luc Pijnenburg
- INSERM (French National Institute of Health and Medical Research), UMR1260, Regenerative Nanomedicine (RNM), FMTS.,Hôpitaux Universitaires de Strasbourg, Strasbourg.,Faculté de Médecine, Université de Strasbourg, Strasbourg
| | - Florence Fioretti
- INSERM (French National Institute of Health and Medical Research), UMR1260, Regenerative Nanomedicine (RNM), FMTS.,Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg.,Hôpitaux Universitaires de Strasbourg, Strasbourg
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR1260, Regenerative Nanomedicine (RNM), FMTS.,Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg.,Faculté de Médecine, Université de Strasbourg, Strasbourg
| | - Anne-Marie Musset
- INSERM (French National Institute of Health and Medical Research), UMR1260, Regenerative Nanomedicine (RNM), FMTS.,Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg.,Hôpitaux Universitaires de Strasbourg, Strasbourg
| |
Collapse
|
27
|
Bugueno IM, Batool F, Keller L, Kuchler-Bopp S, Benkirane-Jessel N, Huck O. Porphyromonas gingivalis bypasses epithelial barrier and modulates fibroblastic inflammatory response in an in vitro 3D spheroid model. Sci Rep 2018; 8:14914. [PMID: 30297793 PMCID: PMC6175856 DOI: 10.1038/s41598-018-33267-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 09/25/2018] [Indexed: 02/07/2023] Open
Abstract
Porphyromonas gingivalis-induced inflammatory effects are mostly investigated in monolayer cultured cells. The aim of this study was to develop a 3D spheroid model of gingiva to take into account epithelio-fibroblastic interactions. Human gingival epithelial cells (ECs) and human oral fibroblasts (FBs) were cultured by hanging drop method to generate 3D microtissue (MT) whose structure was analyzed on histological sections and the cell-to-cell interactions were observed by scanning and transmission electron microscopy (SEM and TEM). MTs were infected by P. gingivalis and the impact on cell death (Apaf-1, caspase-3), inflammatory markers (TNF-α, IL-6, IL-8) and extracellular matrix components (Col-IV, E-cadherin, integrin β1) was evaluated by immunohistochemistry and RT-qPCR. Results were compared to those observed in situ in experimental periodontitis and in human gingival biopsies. MTs exhibited a well-defined spatial organization where ECs were organized in an external cellular multilayer, while, FBs constituted the core. The infection of MT demonstrated the ability of P. gingivalis to bypass the epithelial barrier in order to reach the fibroblastic core and induce disorganization of the spheroid structure. An increased cell death was observed in fibroblastic core. The development of such 3D model may be useful to define the role of EC–FB interactions on periodontal host-immune response and to assess the efficacy of new therapeutics.
Collapse
Affiliation(s)
- Isaac Maximiliano Bugueno
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), 11 rue Humann, Strasbourg, 67000, France.,Université de Strasbourg (UDS), Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, Strasbourg, 67000, France
| | - Fareeha Batool
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), 11 rue Humann, Strasbourg, 67000, France.,Université de Strasbourg (UDS), Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, Strasbourg, 67000, France
| | - Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), 11 rue Humann, Strasbourg, 67000, France.,Université de Strasbourg (UDS), Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, Strasbourg, 67000, France
| | - Sabine Kuchler-Bopp
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), 11 rue Humann, Strasbourg, 67000, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), 11 rue Humann, Strasbourg, 67000, France.,Université de Strasbourg (UDS), Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, Strasbourg, 67000, France
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), 11 rue Humann, Strasbourg, 67000, France. .,Université de Strasbourg (UDS), Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, Strasbourg, 67000, France. .,Hôpitaux Universitaires de Strasbourg (HUS), Department of Periodontology, 1 place de l'Hôpital, Strasbourg, 67000, France.
| |
Collapse
|
28
|
Alhamdi J, Jacobs E, Gronowicz G, Benkirane-Jessel N, Hurley M, Kuhn L. Cell Type Influences Local Delivery of Biomolecules from a Bioinspired Apatite Drug Delivery System. Materials (Basel) 2018; 11:ma11091703. [PMID: 30217000 PMCID: PMC6163578 DOI: 10.3390/ma11091703] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 09/04/2018] [Accepted: 09/07/2018] [Indexed: 01/08/2023]
Abstract
Recently, the benefit of step-wise sequential delivery of fibroblast growth factor-2 (FGF-2) and bone morphogenetic protein-2 from a bioinspired apatite drug delivery system on mouse calvarial bone repair was demonstrated. The thicknesses of the nanostructured poly-l-Lysine/poly-l-Glutamic acid polyelectrolyte multilayer (PEM) and the bone-like apatite barrier layer that make up the delivery system, were varied. The effects of the structural variations of the coating on the kinetics of cell access to a cytotoxic factor delivered by the layered structure were evaluated. FGF-2 was adsorbed into the outer PEM, and cytotoxic antimycin-A (AntiA) was adsorbed to the substrate below the barrier layer to detect the timing of the cell access. While MC3T3-E1 osteoprogenitor cells accessed AntiA after three days, the RAW 264.7 macrophage access occurred within 4 h, unless the PEM layer was removed, in which case the results were reversed. Pits were created in the coating by the RAW 264.7 macrophages and initiated delivery, while the osteoprogenitor cell access to drugs occurred through a solution-mediated coating dissolution, at junctions between the islands of crystals. Macrophage-mediated degradation is therefore a mechanism that controls drug release from coatings containing bioinspired apatite.
Collapse
Affiliation(s)
- Jumana Alhamdi
- Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA.
| | - Emily Jacobs
- Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA.
| | - Gloria Gronowicz
- Department of Surgery, University of Connecticut Health, Farmington, CT 06030, USA.
| | - Nadia Benkirane-Jessel
- French National Institute of Health and Medical Research (INSERM), UMR 1260, Faculté de Médecine, University of Strasbourg, 67085 Strasbourg, France.
| | - Marja Hurley
- Department of Medicine, University of Connecticut Health, Farmington, CT 06030, USA.
| | - Liisa Kuhn
- Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA.
| |
Collapse
|
29
|
Hamaidi I, Coquard C, Danilin S, Dormoy V, Béraud C, Rothhut S, Barthelmebs M, Benkirane-Jessel N, Lindner V, Lang H, Massfelder T. The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma. Oncogene 2018; 38:60-72. [DOI: 10.1038/s41388-018-0413-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2017] [Revised: 06/12/2018] [Accepted: 06/14/2018] [Indexed: 12/13/2022]
|
30
|
Strub M, Keller L, Idoux-Gillet Y, Lesot H, Clauss F, Benkirane-Jessel N, Kuchler-Bopp S. Bone Marrow Stromal Cells Promote Innervation of Bioengineered Teeth. J Dent Res 2018; 97:1152-1159. [PMID: 29879365 DOI: 10.1177/0022034518779077] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Transplantation of bone marrow mesenchymal stem cells (BMDCs) into a denervated side of the spinal cord was reported to be a useful option for axonal regeneration. The innervation of teeth is essential for their function and protection but does not occur spontaneously after injury. Cultured reassociations between dissociated embryonic dental mesenchymal and epithelial cells and implantation lead to a vascularized tooth organ regeneration. However, when reassociations were coimplanted with a trigeminal ganglion (TG), innervation did not occur. On the other hand, reassociations between mixed embryonic dental mesenchymal cells and bone marrow-derived cells isolated from green fluorescent protein (GFP) transgenic mice (BMDCs-GFP) (50/50) with an intact and competent dental epithelium (ED14) were innervated. In the present study, we verified the stemness of isolated BMDCs, confirmed their potential role in the innervation of bioengineered teeth, and analyzed the mechanisms by which this innervation can occur. For that purpose, reassociations between mixed embryonic dental mesenchymal cells and BMDCs-GFP with an intact and competent dental epithelium were cultured and coimplanted subcutaneously with a TG for 2 wk in ICR mice. Axons entered the dental pulp and reached the odontoblast layer. BMDCs-GFP were detected at the base of the tooth, with some being present in the pulp associated with the axons. Thus, while having a very limited contribution in tooth formation, they promoted the innervation of the bioengineered teeth. Using quantitative reverse transcription polymerase chain reaction and immunostainings, BMDCs were shown to promote innervation by 2 mechanisms: 1) via immunomodulation by reducing the number of T lymphocytes (CD3+, CD25+) in the implants and 2) by expressing neurotrophic factors such as NGF, BDNF, and NT3 for axonal growth. This strategy using autologous mesenchymal cells coming from bone marrow could be used to innervate bioengineered teeth without treatment with an immunosuppressor such as cyclosporine A (CsA), thus avoiding multiple side effects.
Collapse
Affiliation(s)
- M Strub
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France.,2 Université de Strasbourg (UDS), Faculté de Chirurgie Dentaire, Strasbourg, France.,3 Hôpitaux Universitaires de Strasbourg (HUS), Department of Pediatric Dentistry, Strasbourg, France
| | - L Keller
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France.,2 Université de Strasbourg (UDS), Faculté de Chirurgie Dentaire, Strasbourg, France
| | - Y Idoux-Gillet
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France.,2 Université de Strasbourg (UDS), Faculté de Chirurgie Dentaire, Strasbourg, France
| | - H Lesot
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France
| | - F Clauss
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France.,2 Université de Strasbourg (UDS), Faculté de Chirurgie Dentaire, Strasbourg, France.,3 Hôpitaux Universitaires de Strasbourg (HUS), Department of Pediatric Dentistry, Strasbourg, France
| | - N Benkirane-Jessel
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France.,2 Université de Strasbourg (UDS), Faculté de Chirurgie Dentaire, Strasbourg, France
| | - S Kuchler-Bopp
- 1 INSERM (French National Institute of Health and Medical Research), Regenerative NanoMedicine (RNM), FMTS, Strasbourg, France
| |
Collapse
|
31
|
Batool F, Strub M, Petit C, Bugueno IM, Bornert F, Clauss F, Huck O, Kuchler-Bopp S, Benkirane-Jessel N. Periodontal Tissues, Maxillary Jaw Bone, and Tooth Regeneration Approaches: From Animal Models Analyses to Clinical Applications. Nanomaterials (Basel) 2018; 8:E337. [PMID: 29772691 PMCID: PMC5977351 DOI: 10.3390/nano8050337] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 05/14/2018] [Accepted: 05/15/2018] [Indexed: 12/13/2022]
Abstract
This review encompasses different pre-clinical bioengineering approaches for periodontal tissues, maxillary jaw bone, and the entire tooth. Moreover, it sheds light on their potential clinical therapeutic applications in the field of regenerative medicine. Herein, the electrospinning method for the synthesis of polycaprolactone (PCL) membranes, that are capable of mimicking the extracellular matrix (ECM), has been described. Furthermore, their functionalization with cyclosporine A (CsA), bone morphogenetic protein-2 (BMP-2), or anti-inflammatory drugs' nanoreservoirs has been demonstrated to induce a localized and targeted action of these molecules after implantation in the maxillary jaw bone. Firstly, periodontal wound healing has been studied in an induced periodontal lesion in mice using an ibuprofen-functionalized PCL membrane. Thereafter, the kinetics of maxillary bone regeneration in a pre-clinical mouse model of surgical bone lesion treated with BMP-2 or BMP-2/Ibuprofen functionalized PCL membranes have been analyzed by histology, immunology, and micro-computed tomography (micro-CT). Furthermore, the achievement of innervation in bioengineered teeth has also been demonstrated after the co-implantation of cultured dental cell reassociations with a trigeminal ganglia (TG) and the cyclosporine A (CsA)-loaded poly(lactic-co-glycolic acid) (PLGA) scaffold in the jaw bone. The prospective clinical applications of these different tissue engineering approaches could be instrumental in the treatment of various periodontal diseases, congenital dental or cranio-facial bone anomalies, and post-surgical complications.
Collapse
Affiliation(s)
- Fareeha Batool
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
| | - Marion Strub
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Departement of Pediatric Dentistry, Pôle de Médecine et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Catherine Petit
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Department of Periodontology, Pôle de Médecine et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Isaac Maximiliano Bugueno
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
| | - Fabien Bornert
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Department of Oral Surgery, Pôle de Médecine et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - François Clauss
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Departement of Pediatric Dentistry, Pôle de Médecine et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Department of Periodontology, Pôle de Médecine et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Sabine Kuchler-Bopp
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), FMTS, 67000 Strasbourg, France.
- Faculty of Dentistry, University of Strasbourg (UDS), 8 rue Ste Elisabeth, 67000 Strasbourg, France.
| |
Collapse
|
32
|
Batool F, Morand DN, Thomas L, Bugueno IM, Aragon J, Irusta S, Keller L, Benkirane-Jessel N, Tenenbaum H, Huck O. Synthesis of a Novel Electrospun Polycaprolactone Scaffold Functionalized with Ibuprofen for Periodontal Regeneration: An In Vitro andIn Vivo Study. Materials (Basel) 2018; 11:ma11040580. [PMID: 29642582 PMCID: PMC5951464 DOI: 10.3390/ma11040580] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 03/29/2018] [Accepted: 04/09/2018] [Indexed: 12/23/2022]
Abstract
Ibuprofen (IBU) has been shown to improve periodontal treatment outcomes. The aim of this study was to develop a new anti-inflammatory scaffold by functionalizing an electrospun nanofibrous poly-ε-caprolactone membrane with IBU (IBU-PCL) and to evaluate its impact on periodontal inflammation, wound healing and regeneration in vitro and in vivo. IBU-PCL was synthesized through electrospinning. The effects of IBU-PCL on the proliferation and migration of epithelial cells (EC) and fibroblasts (FB) exposed to Porphyromonas gingivlais lipopolysaccharide (Pg-LPS) were evaluated through the AlamarBlue test and scratch assay, respectively. Anti-inflammatory and remodeling properties were investigated through Real time qPCR. Finally, the in vivo efficacy of the IBU-PCL membrane was assessed in an experimental periodontitis mouse model through histomorphometric analysis. The results showed that the anti-inflammatory effects of IBU on gingival cells were effectively amplified using the functionalized membrane. IBU-PCL reduced the proliferation and migration of cells challenged by Pg-LPS, as well as the expression of fibronectin-1, collagen-IV, integrin α3β1 and laminin-5. In vivo, the membranes significantly improved the clinical attachment and IBU-PCL also reduced inflammation-induced bone destruction. These data showed that the IBU-PCL membrane could efficiently and differentially control inflammatory and migratory gingival cell responses and potentially promote periodontal regeneration.
Collapse
Affiliation(s)
- Fareeha Batool
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
| | - David-Nicolas Morand
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
| | - Lionel Thomas
- Institute Pluridisciplinaire Hubert CURIEN (IPHC), Strasbourg 67000, France.
| | - Isaac Maximiliano Bugueno
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
| | - Javier Aragon
- Department of Chemical Engineering, Nanoscience Institute of Aragon (INA), University of Zaragoza, 50018 Zaragoza, Spain.
| | - Silvia Irusta
- Department of Chemical Engineering, Nanoscience Institute of Aragon (INA), University of Zaragoza, 50018 Zaragoza, Spain.
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029 Madrid, Spain.
| | - Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
| | - Henri Tenenbaum
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
| | - Olivier Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France.
- Université de Strasbourg, Faculté de Chirurgie-dentaire, 67000 Strasbourg, France.
- Hopitaux Universitaires de Strasbourg, Pôle de médecine et chirurgie bucco-dentaire, Department of Periodontology, 67000 Strasbourg, France.
| |
Collapse
|
33
|
Kuchler-Bopp S, Bagnard D, Van-Der-Heyden M, Idoux-Gillet Y, Strub M, Gegout H, Lesot H, Benkirane-Jessel N, Keller L. Semaphorin 3A receptor inhibitor as a novel therapeutic to promote innervation of bioengineered teeth. J Tissue Eng Regen Med 2018; 12:e2151-e2161. [PMID: 29430872 DOI: 10.1002/term.2648] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 12/15/2017] [Accepted: 01/16/2018] [Indexed: 12/21/2022]
Abstract
The sensory innervation of the dental pulp is essential for tooth function and protection. It is mediated by axons originating from the trigeminal ganglia and is spatio-temporally regulated. We have previously shown that the innervation of bioengineered teeth can be achieved only under immunosuppressive conditions. The aim of this study was to develop a model to determine the role of Semaphorin 3A (Sema3A) in the innervation of bioengineered teeth. We first analysed innervation of the dental pulp of mandibular first molars in newborn (postnatal day 0: PN0) mice deficient for Sema3A (Sema3A-/- ), a strong inhibitor of axon growth. While at PN0, axons detected by immunostaining for peripherin and NF200 were restricted to the peridental mesenchyme in Sema3A+/+ mice, they entered the dental pulp in Sema3A-/- mice. Then, we have implanted cultured teeth obtained from embryonic day-14 (E14) molar germs of Sema3A-/- mice together with trigeminal ganglia. The dental pulps of E14 cultured and implanted Sema3A-/- teeth were innervated, whereas the axons did not enter the pulp of E14 Sema3A+/+ cultured and implanted teeth. A "Membrane Targeting Peptide NRP1," suppressing the inhibitory effect of Sema3A, has been previously identified. The injection of this peptide at the site of implantation allowed the innervation of the dental pulp of bioengineered teeth obtained from E14 dental dissociated mesenchymal and epithelial cells reassociations of ICR mice. In conclusion, these data show that inhibition of only one axon repellent molecule, Sema3A, allows for pulp innervation of bioengineered teeth.
Collapse
Affiliation(s)
- Sabine Kuchler-Bopp
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg
| | - Dominique Bagnard
- INSERM, UMR 1119-Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, Fédération de Médecine Translationnelle, Labex Medalis, University of Strasbourg, Strasbourg, France
| | - Michael Van-Der-Heyden
- INSERM, UMR 1119-Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, Fédération de Médecine Translationnelle, Labex Medalis, University of Strasbourg, Strasbourg, France
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, 67000, Strasbourg, France
| | - Marion Strub
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, 67000, Strasbourg, France.,Hôpitaux universitaires de Strasbourg (HUS), Département de Pédodontie, 1 place de l'Hôpital, 67000, Strasbourg
| | - Hervé Gegout
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, 67000, Strasbourg, France
| | - Hervé Lesot
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, 67000, Strasbourg, France
| | - Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000, Strasbourg.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, 67000, Strasbourg, France
| |
Collapse
|
34
|
Van Bellinghen X, Idoux-Gillet Y, Pugliano M, Strub M, Bornert F, Clauss F, Schwinté P, Keller L, Benkirane-Jessel N, Kuchler-Bopp S, Lutz JC, Fioretti F. Temporomandibular Joint Regenerative Medicine. Int J Mol Sci 2018; 19:E446. [PMID: 29393880 PMCID: PMC5855668 DOI: 10.3390/ijms19020446] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 01/19/2018] [Accepted: 01/29/2018] [Indexed: 01/09/2023] Open
Abstract
The temporomandibular joint (TMJ) is an articulation formed between the temporal bone and the mandibular condyle which is commonly affected. These affections are often so painful during fundamental oral activities that patients have lower quality of life. Limitations of therapeutics for severe TMJ diseases have led to increased interest in regenerative strategies combining stem cells, implantable scaffolds and well-targeting bioactive molecules. To succeed in functional and structural regeneration of TMJ is very challenging. Innovative strategies and biomaterials are absolutely crucial because TMJ can be considered as one of the most difficult tissues to regenerate due to its limited healing capacity, its unique histological and structural properties and the necessity for long-term prevention of its ossified or fibrous adhesions. The ideal approach for TMJ regeneration is a unique scaffold functionalized with an osteochondral molecular gradient containing a single stem cell population able to undergo osteogenic and chondrogenic differentiation such as BMSCs, ADSCs or DPSCs. The key for this complex regeneration is the functionalization with active molecules such as IGF-1, TGF-β1 or bFGF. This regeneration can be optimized by nano/micro-assisted functionalization and by spatiotemporal drug delivery systems orchestrating the 3D formation of TMJ tissues.
Collapse
Affiliation(s)
- Xavier Van Bellinghen
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Médecine et Chirurgie Bucco-Dentaires & Chirurgie Maxillo-Facial, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
| | - Marion Pugliano
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
| | - Marion Strub
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Médecine et Chirurgie Bucco-Dentaires & Chirurgie Maxillo-Facial, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Fabien Bornert
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Médecine et Chirurgie Bucco-Dentaires & Chirurgie Maxillo-Facial, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Francois Clauss
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Médecine et Chirurgie Bucco-Dentaires & Chirurgie Maxillo-Facial, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| | - Pascale Schwinté
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
| | - Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
| | - Sabine Kuchler-Bopp
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
| | - Jean Christophe Lutz
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Médecine et Chirurgie Bucco-Dentaires & Chirurgie Maxillo-Facial, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
- Faculté de Médecine, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France.
| | - Florence Fioretti
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 11 rue Humann, 67000 Strasbourg, France.
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 rue Ste Elisabeth, 67000 Strasbourg, France.
- Médecine et Chirurgie Bucco-Dentaires & Chirurgie Maxillo-Facial, Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, 67000 Strasbourg, France.
| |
Collapse
|
35
|
Fernandez de Grado G, Keller L, Idoux-Gillet Y, Wagner Q, Musset AM, Benkirane-Jessel N, Bornert F, Offner D. Bone substitutes: a review of their characteristics, clinical use, and perspectives for large bone defects management. J Tissue Eng 2018; 9:2041731418776819. [PMID: 29899969 PMCID: PMC5990883 DOI: 10.1177/2041731418776819] [Citation(s) in RCA: 356] [Impact Index Per Article: 59.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Accepted: 04/24/2018] [Indexed: 12/13/2022] Open
Abstract
Bone replacement might have been practiced for centuries with various materials of natural origin, but had rarely met success until the late 19th century. Nowadays, many different bone substitutes can be used. They can be either derived from biological products such as demineralized bone matrix, platelet-rich plasma, hydroxyapatite, adjunction of growth factors (like bone morphogenetic protein) or synthetic such as calcium sulfate, tri-calcium phosphate ceramics, bioactive glasses, or polymer-based substitutes. All these substitutes are not suitable for every clinical use, and they have to be chosen selectively depending on their purpose. Thus, this review aims to highlight the principal characteristics of the most commonly used bone substitutes and to give some directions concerning their clinical use, as spine fusion, open-wedge tibial osteotomy, long bone fracture, oral and maxillofacial surgery, or periodontal treatments. However, the main limitations to bone substitutes use remain the management of large defects and the lack of vascularization in their central part, which is likely to appear following their utilization. In the field of bone tissue engineering, developing porous synthetic substitutes able to support a faster and a wider vascularization within their structure seems to be a promising way of research.
Collapse
Affiliation(s)
- Gabriel Fernandez de Grado
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
- Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, F-67000 Strasbourg
| | - Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
| | - Quentin Wagner
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
| | - Anne-Marie Musset
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
- Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, F-67000 Strasbourg
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
| | - Fabien Bornert
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
- Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, F-67000 Strasbourg
| | - Damien Offner
- INSERM (French National Institute of Health and Medical Research), “Regenerative Nanomedicine” laboratory, http://www.regmed.fr, UMR 1260, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Ste Elisabeth, F-67000 Strasbourg
- Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, F-67000 Strasbourg
| |
Collapse
|
36
|
Schwinté P, Mariotte A, Anand P, Keller L, Idoux-Gillet Y, Huck O, Fioretti F, Tenenbaum H, Georgel P, Wenzel W, Irusta S, Benkirane-Jessel N. Anti-inflammatory effect of active nanofibrous polymeric membrane bearing nanocontainers of atorvastatin complexes. Nanomedicine (Lond) 2017; 12:2651-2674. [DOI: 10.2217/nnm-2017-0198] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: We developed polymeric membranes for local administration of nonsoluble anti-inflammatory statin, as potential wound patch in rheumatic joint or periodontal lesions. Methods: Electrospun polycaprolactone membranes were fitted with polysaccharide-atorvastatin nanoreservoirs by using complexes with poly-aminocyclodextrin. Characterization methods are UV-Visible and X-ray photoelectron spectroscopy, molecular dynamics, scanning and transmission electron microscopy. In vitro, membranes were seeded with macrophages, and inflammatory cytokine expression were monitored. Results & conclusion: Stable inclusion complexes were formed in solution (1:1 stability constant 368 M- 1, -117.40 kJ mol- 1), with supramolecular globular organization (100 nm, substructure 30 nm). Nanoreservoir technology leads to homogeneous distribution of atorvastatin calcium trihydrate complexes in the membrane. Quantity embedded was estimated (70–90 μg in 30 μm × 6 mm membrane). Anti-inflammatory effect by cell contact-dependent release reached 60% inhibition for TNF-α and 80% for IL-6. The novelty resides in the double protection offered by the cyclodextrins as drug molecular chaperones, with further embedding into biodegradable nanoreservoirs. The strategy is versatile and can target other diseases.
Collapse
Affiliation(s)
- Pascale Schwinté
- INSERM (French National Institute of Health & Medical Research), UMR 1109, “Osteoarticular & Dental Regenerative Nanomedicine”, Faculté de Médecine, 11 rue Humann, FMTS, Strasbourg, F-67085, France
| | - Alexandre Mariotte
- INSERM UMR 1109, Molecular ImmunoRheumatology, LabEx TRANSPLANTEX, Faculté de Médecine, Center de Recherche d'Immunologie et d'Hématologie, 4 rue Kirschleger, FMTS, Université de Strasbourg, Strasbourg, F-67085, France
| | - Priya Anand
- Institute of Nanotechnology, Karlsruhe Institute of Technology, KIT Campus North, Hermann-von-Helmholtz-Platz 1, Building 640, Eggenstein-Leopoldshafen, D-76344, Germany
| | - Laetitia Keller
- INSERM (French National Institute of Health & Medical Research), UMR 1109, “Osteoarticular & Dental Regenerative Nanomedicine”, Faculté de Médecine, 11 rue Humann, FMTS, Strasbourg, F-67085, France
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health & Medical Research), UMR 1109, “Osteoarticular & Dental Regenerative Nanomedicine”, Faculté de Médecine, 11 rue Humann, FMTS, Strasbourg, F-67085, France
| | - Olivier Huck
- INSERM (French National Institute of Health & Medical Research), UMR 1109, “Osteoarticular & Dental Regenerative Nanomedicine”, Faculté de Médecine, 11 rue Humann, FMTS, Strasbourg, F-67085, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 1 place de l'Hôpital, Strasbourg F-67085, France
| | - Florence Fioretti
- INSERM (French National Institute of Health & Medical Research), UMR 1109, “Osteoarticular & Dental Regenerative Nanomedicine”, Faculté de Médecine, 11 rue Humann, FMTS, Strasbourg, F-67085, France
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 1 place de l'Hôpital, Strasbourg F-67085, France
| | - Henri Tenenbaum
- Faculté de Chirurgie Dentaire, Université de Strasbourg, 1 place de l'Hôpital, Strasbourg F-67085, France
| | - Philippe Georgel
- INSERM UMR 1109, Molecular ImmunoRheumatology, LabEx TRANSPLANTEX, Faculté de Médecine, Center de Recherche d'Immunologie et d'Hématologie, 4 rue Kirschleger, FMTS, Université de Strasbourg, Strasbourg, F-67085, France
| | - Wolfgang Wenzel
- Institute of Nanotechnology, Karlsruhe Institute of Technology, KIT Campus North, Hermann-von-Helmholtz-Platz 1, Building 640, Eggenstein-Leopoldshafen, D-76344, Germany
| | - Silvia Irusta
- Department of Chemical Engineering & Aragon Nanoscience Institute, University of Zaragoza, C/Mariano Esquillor, s/n, Zaragoza, 50018, Spain
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health & Medical Research), UMR 1109, “Osteoarticular & Dental Regenerative Nanomedicine”, Faculté de Médecine, 11 rue Humann, FMTS, Strasbourg, F-67085, France
| |
Collapse
|
37
|
Zhao Y, Zhang Q, Zhao L, Gan L, Yi L, Zhao Y, Xue J, Luo L, Du Q, Geng R, Sun Z, Benkirane-Jessel N, Chen P, Li Y, Chen Y. Enhanced Peripheral Nerve Regeneration by a High Surface Area to Volume Ratio of Nerve Conduits Fabricated from Hydroxyethyl Cellulose/Soy Protein Composite Sponges. ACS Omega 2017; 2:7471-7481. [PMID: 30023554 PMCID: PMC6044839 DOI: 10.1021/acsomega.7b01003] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2017] [Accepted: 10/19/2017] [Indexed: 05/05/2023]
Abstract
Multichannel nerve guide conduits (MCNGCs) have been widely studied and exhibited outstanding nerve repair function. However, the effect of the geometric structure of MCNGCs on the nerve repair function was still not clear. Herein, we postulated that MCNGCs with different inner surface area-to-volume ratios (ISA/V) of the channels inside the nerve guide conduits (NGCs) would show different nerve repair functions. Therefore, in current work, we constructed a series of hydroxyethyl cellulose/soy protein sponge-based nerve conduit (HSSN) with low, medium, and high ISA/V from hydroxyethyl cellulose (HEC)/soy protein isolate (SPI) composite sponges, which were abbreviated as HSSN-L, HSSN-M and HSSN-H, respectively. These NGCs were applied to bridge and repair a 10 mm long sciatic nerve defect in a rat model. Finally, the influence of ISA/V on nerve repair function was evaluated by electrophysiological assessment, histological investigation, and in vivo biodegradability testing. The results of electrophysiological assessment and histological investigation showed that the regenerative nerve tissues bridged with HSSN-H and HSSN-M had higher compound muscle action potential amplitude ratio, higher percentage of positive NF200 and S100 staining, larger axon diameter, lower G-ratio, and greater myelination thickness. Furthermore, the regenerative nerve tissues bridged with HSSN-H also showed higher density of regenerated myelinated nerve fibers and more number of myelin sheath layers. On the whole, the repair efficiency of the peripheral nerve in HSSN-H and HSSN-M groups might be better than that in HSSN-L. These results indicated that higher ISA/V based on HEC/SPI composite sponge may result in greater nerve repair functions. The conclusion provided a probable guiding principle for the structural designs of NGCs in the future.
Collapse
Affiliation(s)
- Yanteng Zhao
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
- Department
of Transfusion, The First Affiliated Hospital
of Zhengzhou University, Zhengzhou 450052, China
| | - Qiang Zhang
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Lei Zhao
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Li Gan
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
- Department
of Cell Biology, School of Medicine, Wuhan
University of Science and Technology, Wuhan 430065, China
| | - Li Yi
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Yanan Zhao
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Jingling Xue
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Lihua Luo
- Laboratory
of Stem Cells and Tissue Engineering, School & Hospital of Stomatology, Wenzhou Medical University, Wenzhou 325027, China
| | - Qiaoyue Du
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Rongxin Geng
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Zhihong Sun
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Nadia Benkirane-Jessel
- INSERM
(French National Institute of Health and Medical Research), Osteoarticular
and Dental Regenerative Nanomedicine Laboratory, UMR 1109, Faculté
de Médecine, Strasbourg F-67000, France
- Université
de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l’Hôpital, Strasbourg F-67000, France
| | - Pu Chen
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
| | - Yinping Li
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
- E-mail: (Y.L.)
| | - Yun Chen
- Department
of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
- E-mail: (Y.C.)
| |
Collapse
|
38
|
Bugueno IM, Batool F, Korah L, Benkirane-Jessel N, Huck O. Porphyromonas gingivalis Differentially Modulates Apoptosome Apoptotic Peptidase Activating Factor 1 in Epithelial Cells and Fibroblasts. Am J Pathol 2017; 188:404-416. [PMID: 29154960 DOI: 10.1016/j.ajpath.2017.10.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 09/21/2017] [Accepted: 10/03/2017] [Indexed: 12/11/2022]
Abstract
Porphyromonas gingivalis is able to invade and modulate host-immune response to promote its survival. This bacterium modulates the cell cycle and programed cell death, contributing to periodontal lesion worsening. Several molecular pathways have been identified as key triggers of apoptosis, including apoptosome apoptotic peptidase activating factor 1 (APAF-1). Apaf-1 and X-linked inhibitor of apoptosis protein (Xiap) mRNA were differentially expressed between gingival samples harvested from human healthy and chronic periodontitis tissues (Apaf-1, 19.2-fold; caspase-9, 14.5-fold; caspase-3, 6.8-fold; Xiap: 2.5-fold in chronic periodontitis) (P < 0.05), highlighting their potential role in periodontitis. An increased proteic expression of APAF-1 was also observed in a murine experimental periodontitis model induced by P. gingivalis-soaked ligatures. In vitro, it was observed that P. gingivalis targets APAF-1, XIAP, caspase-3, and caspase-9, to inhibit epithelial cell death at both mRNA and protein levels. Opposite effect was observed in fibroblasts in which P. gingivalis increased cell death and apoptosis. To assess if the observed effects were associated to APAF-1, epithelial cells and fibroblasts were transfected with siRNA targeting Apaf-1. Herein, we confirmed that APAF-1 is targeted by P. gingivalis in both cell types. This study identified APAF-1 apoptosome and XIAP as intracellular targets of P. gingivalis, contributing to the deterioration of periodontal lesion through an increased persistence of the bacteria within tissues and the subversion of host-immune response.
Collapse
Affiliation(s)
- Isaac M Bugueno
- INSERM 1260 Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Fareeha Batool
- INSERM 1260 Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Linda Korah
- INSERM 1260 Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM 1260 Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Olivier Huck
- INSERM 1260 Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Faculty of Dental Surgery, Periodontology, Université de Strasbourg, Strasbourg, France.
| |
Collapse
|
39
|
Chaddad H, Kuchler-Bopp S, Fuhrmann G, Gegout H, Ubeaud-Sequier G, Schwinté P, Bornert F, Benkirane-Jessel N, Idoux-Gillet Y. Combining 2D angiogenesis and 3D osteosarcoma microtissues to improve vascularization. Exp Cell Res 2017; 360:138-145. [PMID: 28867479 DOI: 10.1016/j.yexcr.2017.08.035] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 08/23/2017] [Accepted: 08/24/2017] [Indexed: 12/12/2022]
Abstract
Angiogenesis is now well known for being involved in tumor progression, aggressiveness, emergence of metastases, and also resistance to cancer therapies. In this study, to better mimic tumor angiogenesis encountered in vivo, we used 3D culture of osteosarcoma cells (MG-63) that we deposited on 2D endothelial cells (HUVEC) grown in monolayer. We report that endothelial cells combined with tumor cells were able to form a well-organized network, and that tubule-like structures corresponding to new vessels infiltrate tumor spheroids. These vessels presented a lumen and expressed specific markers as CD31 and collagen IV. The combination of 2D endothelial cells and 3D microtissues of tumor cells also increased expression of angiogenic factors as VEGF, CXCR4 and ICAM1. The cell environment is the key point to develop tumor vascularization in vitro and to be closer to tumor encountered in vivo.
Collapse
Affiliation(s)
- Hassan Chaddad
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, UMR CNRS 7213, EA7293, Faculté de Pharmacie, route du Rhin, 67401 Illkirch-Graffenstaden, France
| | - Sabine Kuchler-Bopp
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg F-67000, France
| | - Guy Fuhrmann
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, UMR CNRS 7213, EA7293, Faculté de Pharmacie, route du Rhin, 67401 Illkirch-Graffenstaden, France
| | - Hervé Gegout
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg F-67000, France
| | - Geneviève Ubeaud-Sequier
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, UMR CNRS 7213, EA7293, Faculté de Pharmacie, route du Rhin, 67401 Illkirch-Graffenstaden, France
| | - Pascale Schwinté
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg F-67000, France
| | - Fabien Bornert
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg F-67000, France
| | - Nadia Benkirane-Jessel
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg F-67000, France.
| | - Ysia Idoux-Gillet
- INSERM, UMR 1109, Osteoarticular and Dental Regenerative NanoMedicine Laboratory, FMTS, 11 rue Humann, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg F-67000, France.
| |
Collapse
|
40
|
Schiavi J, Reppel L, Charif N, de Isla N, Mainard D, Benkirane-Jessel N, Stoltz JF, Rahouadj R, Huselstein C. Mechanical stimulations on human bone marrow mesenchymal stem cells enhance cells differentiation in a three-dimensional layered scaffold. J Tissue Eng Regen Med 2017; 12:360-369. [PMID: 28486755 DOI: 10.1002/term.2461] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 03/20/2017] [Accepted: 05/04/2017] [Indexed: 11/05/2022]
Abstract
Scaffolds laden with stem cells are a promising approach for articular cartilage repair. Investigations have shown that implantation of artificial matrices, growth factors or chondrocytes can stimulate cartilage formation, but no existing strategies apply mechanical stimulation on stratified scaffolds to mimic the cartilage environment. The purpose of this study was to adapt a spraying method for stratified cartilage engineering and to stimulate the biosubstitute. Human mesenchymal stem cells from bone marrow were seeded in an alginate (Alg)/hyaluronic acid (HA) or Alg/hydroxyapatite (Hap) gel to direct cartilage and hypertrophic cartilage/subchondral bone differentiation, respectively, in different layers within a single scaffold. Homogeneous or composite stratified scaffolds were cultured for 28 days and cell viability and differentiation were assessed. The heterogeneous scaffold was stimulated daily. The mechanical behaviour of the stratified scaffolds were investigated by plane-strain compression tests. Results showed that the spraying process did not affect cell viability. Moreover, cell differentiation driven by the microenvironment was increased with loading: in the layer with Alg/HA, a specific extracellular matrix of cartilage, composed of glycosaminoglycans and type II collagen was observed, and in the Alg/Hap layer more collagen X was detected. Hap seemed to drive cells to a hypertrophic chondrocytic phenotype and increased mechanical resistance of the scaffold. In conclusion, mechanical stimulations will allow for the production of a stratified biosubstitute, laden with human mesenchymal stem cells from bone marrow, which is capable in vivo to mimic all depths of chondral defects, thanks to an efficient combination of stem cells, biomaterial compositions and mechanical loading.
Collapse
Affiliation(s)
- Jessica Schiavi
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France
| | - Loïc Reppel
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France.,CHRU de Nancy, Unité de Thérapie Cellulaire et Tissulaire, Vandœuvre-lès-Nancy, France
| | - Naceur Charif
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France
| | - Natalia de Isla
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France
| | - Didier Mainard
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France.,CHRU de Nancy, Chirurgie Orthopédique et Traumatologique, Nancy, France
| | | | - Jean-François Stoltz
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France.,CHRU de Nancy, Unité de Thérapie Cellulaire et Tissulaire, Vandœuvre-lès-Nancy, France
| | - Rachid Rahouadj
- CNRS - UMR 7563 - Lorraine University, Vandœuvre-lès-Nancy, France
| | - Céline Huselstein
- CNRS UMR 7365 - Lorraine University, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Biopôle, Vandœuvre-lès-Nancy, France.,Fédération de Recherche 3209, Bioingénierie Moléculaire Cellulaire et Thérapeutique, Vandœuvre-lès-Nancy, France
| |
Collapse
|
41
|
Offner D, Wagner Q, Idoux-Gillet Y, Gegout H, Ferrandon A, Schwinté P, Musset AM, Benkirane-Jessel N, Keller L. Hybrid collagen sponge and stem cells as a new combined scaffold able to induce the re-organization of endothelial cells into clustered networks. Biomed Mater Eng 2017; 28:S185-S192. [PMID: 28372294 DOI: 10.3233/bme-171640] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The time needed to obtain functional regenerated bone tissue depends on the existence of a reliable vascular support. Current techniques used in clinic, for example after tooth extraction, do not allow regaining or preserving the same bone volume. Our aim is to develop a cellularized active implant of the third generation, equipped with human mesenchymal stem cells to improve the quality of implant vascularization. We seeded a commercialized collagen implant with human mesenchymal stem cells (hMSCs) and then with human umbilical vein endothelial cells (HUVECs). We analyzed the biocompatibility and the behavior of endothelial cells with this implant. We observed a biocompatibility of the active implant, and a re-organization of endothelial cells into clustered networks. This work shows the possibility to develop an implant of the third generation supporting vascularization, improving the medical care of patients.
Collapse
Affiliation(s)
- Damien Offner
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France.,Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Quentin Wagner
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| | - Hervé Gegout
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| | - Arielle Ferrandon
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| | - Pascale Schwinté
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| | - Anne-Marie Musset
- Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France.,Hôpitaux Universitaires de Strasbourg (HUS), 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| | - Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), 'Osteoarticular and Dental Regenerative Nanomedicine' Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg cedex, FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, F-67000 Strasbourg, France
| |
Collapse
|
42
|
Keller L, Regiel-Futyra A, Gimeno M, Eap S, Mendoza G, Andreu V, Wagner Q, Kyzioł A, Sebastian V, Stochel G, Arruebo M, Benkirane-Jessel N. Chitosan-based nanocomposites for the repair of bone defects. Nanomedicine 2017. [PMID: 28647591 DOI: 10.1016/j.nano.2017.06.007] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Chitosan scaffolds of different deacetylation degrees, average molecular weights and concentrations reinforced with silica nanoparticles were prepared for bone tissue regeneration. The resulting nanocomposites showed similar pore sizes (<300 μm) regardless the deacetylation degree and concentration used in their formulation. Their mechanical compression resistance was increased by a 30% with the addition of silica nanoparticles as nanofillers. The biocompatibility of the three-dimensional chitosan scaffolds was confirmed by the Alamar Blue assay in human primary osteoblasts as well as the formation of cell spheroids indicative of their great potential for bone regeneration. In vivo implantation of the scaffolds in a mice calvaria defect model provided substantial evidences of the suitability of these nanocomposites for bone tissue engineering showing a mature and dense collagenous tissue with small foci of mineralization, vascularized areas and the infiltration of osteoblasts and osteoclasts. Nevertheless, mature bone tissue formation was not observed after eight weeks of implantation.
Collapse
Affiliation(s)
- L Keller
- INSERM, Unité Mixte de Recherche UMR 1109, Team "Osteoarticular and Dental Regenerative NanoMedicine," Fédération de Médecine Translationnelle de Strasbourg, Faculté de Chirurgie Dentaire, UDS, Strasbourg, France
| | - A Regiel-Futyra
- Faculty of Chemistry, Jagiellonian University, Kraków, Poland
| | - M Gimeno
- Faculty of Veterinary, Department of Animal Pathology, University of Zaragoza, Spain
| | - S Eap
- INSERM, Unité Mixte de Recherche UMR 1109, Team "Osteoarticular and Dental Regenerative NanoMedicine," Fédération de Médecine Translationnelle de Strasbourg, Faculté de Chirurgie Dentaire, UDS, Strasbourg, France
| | - G Mendoza
- Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029, Madrid, Spain; Aragon Health Research Institute (IIS Aragón), 50009, Zaragoza, Spain.
| | - V Andreu
- Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029, Madrid, Spain; Aragon Health Research Institute (IIS Aragón), 50009, Zaragoza, Spain.
| | - Q Wagner
- INSERM, Unité Mixte de Recherche UMR 1109, Team "Osteoarticular and Dental Regenerative NanoMedicine," Fédération de Médecine Translationnelle de Strasbourg, Faculté de Chirurgie Dentaire, UDS, Strasbourg, France
| | - A Kyzioł
- Faculty of Chemistry, Jagiellonian University, Kraków, Poland
| | - V Sebastian
- Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029, Madrid, Spain; Aragon Health Research Institute (IIS Aragón), 50009, Zaragoza, Spain
| | - G Stochel
- Faculty of Chemistry, Jagiellonian University, Kraków, Poland
| | - M Arruebo
- Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029, Madrid, Spain; Aragon Health Research Institute (IIS Aragón), 50009, Zaragoza, Spain
| | - N Benkirane-Jessel
- INSERM, Unité Mixte de Recherche UMR 1109, Team "Osteoarticular and Dental Regenerative NanoMedicine," Fédération de Médecine Translationnelle de Strasbourg, Faculté de Chirurgie Dentaire, UDS, Strasbourg, France
| |
Collapse
|
43
|
Elkaim R, Bugueno-Valdebenito IM, Benkirane-Jessel N, Tenenbaum H. Porphyromonas gingivalis and its LPS differentially regulate the expression of peptidyl arginine deiminases in human chondrocytes. Innate Immun 2017. [PMID: 28633586 DOI: 10.1177/1753425917716266] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Periodontitis, an inflammatory disease initiated by Gram-negative bacteria such as Porphyromonas gingivalis ( Pg), is considered as a risk factor for rheumatoid arthritis (RA). Our study aimed to determine the effect of Pg and its LPS on the expression of peptidyl arginine deiminase isotypes (PADs) in human primary chondrocytes (HC). HCs were infected with Pg and activated by its LPS (LPS- Pg). The mRNA expression levels of human PADs (1, 2, 3, 4 and 6) and bacterial enzyme (PADPg) were quantified by RT-qPCR. Cellular extracts served to measure the enzymatic activities of PADs and PADPg and to visualize the profiles of citrullinated proteins/peptides by Western blotting. Our data showed significant inhibitions of mRNA expressions of human PAD-2, PAD-3 and PAD-4 during infection of HC with live Pg. Activation of HC by LPS- Pg increased mRNA expressions of human PAD-2 and PAD-3. The PADPg enzymatic activity was significantly increased in only infected HC. Analysis of citrullinated proteins/peptides profiles revealed the occurrence of low molecular bands only in cellular extracts from HC infected with Pg. Our data showed that Pg and its LPS differentially regulate the expression of PADs in human chondrocytes and that Pg favors the apparition of new citrullinated proteins/peptides.
Collapse
Affiliation(s)
- René Elkaim
- 1 INSERM "Osteoarticular and Dental Regenerative Nanomedicine" laboratory, UMR 1109, Medical Faculty, Strasbourg Cedex, France.,2 University of Strasbourg, Dental Faculty, Strasbourg, France
| | | | - Nadia Benkirane-Jessel
- 1 INSERM "Osteoarticular and Dental Regenerative Nanomedicine" laboratory, UMR 1109, Medical Faculty, Strasbourg Cedex, France
| | - Henri Tenenbaum
- 1 INSERM "Osteoarticular and Dental Regenerative Nanomedicine" laboratory, UMR 1109, Medical Faculty, Strasbourg Cedex, France.,2 University of Strasbourg, Dental Faculty, Strasbourg, France
| |
Collapse
|
44
|
Elkaim R, Bugueno-Valdebenito IM, Benkirane-Jessel N, Tenenbaum H. Porphyromonas gingivalis and its lipopolysaccharide differently modulate epidermal growth factor-dependent signaling in human gingival epithelial cells. J Oral Microbiol 2017; 9:1334503. [PMID: 28748038 PMCID: PMC5508388 DOI: 10.1080/20002297.2017.1334503] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 05/11/2017] [Indexed: 11/16/2022] Open
Abstract
Periodontitis is an inflammatory disease induced by pathogenic bacteria such as Porphyromonas gingivalis. Little is known about epidermal growth factor (EGF) signals in human gingival epithelial cells (HGEC), which are major targets of P. gingivalis, and how the expression of proteins participating in EGF signaling—that is, EGF-receptor (EGFR), suppressor of cytokine signaling-3 (SOCS-3), interferon regulatory factor-1 (IRF-1), and signal transducers and activators of transcription (STAT-3)—are modified. This study aimed to assess the effects of P. gingivalis and its purified lipopolysaccharide (LPS-Pg) on EGF signaling. HGEC were infected for 2 h in a dose-dependent manner with P. gingivalis and with heat-killed P. gingivalis, and activated for 2 and 24 h by 1 µg/mL of purified LPS-Pg. Quantitative reverse transcription polymerase chain reaction and Western blotting were performed to measure mRNA and protein levels for SOCS-3, IRF-1 EGF, EGFR, and STAT-3. The tyrosine-phosphorylation status of STAT-3 was also examined. The results showed that infection of HGEC cells with P. gingivalis, but not with heat-killed P. gingivalis, led to significant reductions in expression levels of mRNAs and proteins for SOCS-3, IRF-1, and EGFR, while LPS-Pg over time significantly increased the expression of these mRNAs and proteins. Tyrosine-phosphorylation of STAT-3 was significantly increased during infection with P. gingivalis and activation by LPS-Pg but not modified during infection with heat-killed P. gingivalis. This study highlights that P. gingivalis and its purified LPS differentially modulated the expression of proteins (SOCS-3, IRF-1, EGFR, and STAT-3) interfering with EGF signaling.
Collapse
Affiliation(s)
- R Elkaim
- INSERM 1109 'Osteoarticular and Dental Regenerative Nanomedicine', Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - I M Bugueno-Valdebenito
- INSERM 1109 'Osteoarticular and Dental Regenerative Nanomedicine', Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - N Benkirane-Jessel
- INSERM 1109 'Osteoarticular and Dental Regenerative Nanomedicine', Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - H Tenenbaum
- University of Strasbourg, Dental Faculty, Strasbourg, France
| |
Collapse
|
45
|
Prakash Parthiban S, Rana D, Jabbari E, Benkirane-Jessel N, Ramalingam M. Covalently immobilized VEGF-mimicking peptide with gelatin methacrylate enhances microvascularization of endothelial cells. Acta Biomater 2017; 51:330-340. [PMID: 28110074 DOI: 10.1016/j.actbio.2017.01.046] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2016] [Revised: 12/16/2016] [Accepted: 01/16/2017] [Indexed: 01/11/2023]
Abstract
Clinically usable tissue-engineered constructs are currently limited due to their inability of forming microvascular networks necessary for adequate cellular oxygen and nutrient supply upon implantation. The aim of this study is to investigate the conditions necessary for microvascularization in a tissue-engineered construct using vascular endothelial growth factor (VEGF). The construct was made of gelatin methacrylate (GelMA) based cell-laden hydrogel system, which was then covalently linked with VEGF-mimicking peptide (AcQK), using human umbilical vein endothelial cells (HUVECs) as the model cell. The results of the mechanics and gene expression analysis indicated significant changes in mechanical properties and upregulation of vascular-specific genes. The major finding of this study is that the increased expression of vascular-specific genes could be achieved by employing AcQK in the GelMA based hydrogel system, leading to accelerated microvascularization. We conclude that GelMA with covalently-linked angiogenic peptide is a useful tissue engineered construct suitable for microvascularization. STATEMENT OF SIGNIFICANCE: (1) This study reports the conditions necessary for microvascularization in a tissue-engineered construct using vascular endothelial growth factor (VEGF). (2) The construct was made of gelatin methacrylate based cell-laden hydrogel system. (3) There is a significant change observed in mechanical properties and upregulation of vascular-specific genes, in particular CD34, when AcQK is used. (4) The major finding of this study is that the increased expression of vascular-specific genes, i.e., CD34 could be achieved by employing AcQK in the GelMA based hydrogel system, leading to accelerated microvascularization.
Collapse
|
46
|
Keller L, Idoux-Gillet Y, Wagner Q, Eap S, Brasse D, Schwinté P, Arruebo M, Benkirane-Jessel N. Nanoengineered implant as a new platform for regenerative nanomedicine using 3D well-organized human cell spheroids. Int J Nanomedicine 2017; 12:447-457. [PMID: 28138241 PMCID: PMC5238755 DOI: 10.2147/ijn.s116749] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
In tissue engineering, it is still rare today to see clinically transferable strategies for tissue-engineered graft production that conclusively offer better tissue regeneration than the already existing technologies, decreased recovery times, and less risk of complications. Here a novel tissue-engineering concept is presented for the production of living bone implants combining 1) a nanofibrous and microporous implant as cell colonization matrix and 2) 3D bone cell spheroids. This combination, double 3D implants, shows clinical relevant thicknesses for the treatment of an early stage of bone lesions before the need of bone substitutes. The strategy presented here shows a complete closure of a defect in nude mice calvaria after only 31 days. As a novel strategy for bone regenerative nanomedicine, it holds great promises to enhance the therapeutic efficacy of living bone implants.
Collapse
Affiliation(s)
- Laetitia Keller
- INSERM (French National Institute of Health and Medical Research), “Osteoarticular and Dental Regenerative Nanomedicine” Laboratory, UMR 1109, Faculté de Médecine, FMTS
- University of Strasbourg, Faculté de Chirurgie Dentaire
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health and Medical Research), “Osteoarticular and Dental Regenerative Nanomedicine” Laboratory, UMR 1109, Faculté de Médecine, FMTS
- University of Strasbourg, Faculté de Chirurgie Dentaire
| | - Quentin Wagner
- INSERM (French National Institute of Health and Medical Research), “Osteoarticular and Dental Regenerative Nanomedicine” Laboratory, UMR 1109, Faculté de Médecine, FMTS
- University of Strasbourg, Faculté de Chirurgie Dentaire
| | - Sandy Eap
- INSERM (French National Institute of Health and Medical Research), “Osteoarticular and Dental Regenerative Nanomedicine” Laboratory, UMR 1109, Faculté de Médecine, FMTS
- University of Strasbourg, Faculté de Chirurgie Dentaire
| | - David Brasse
- CNRS (Centre National de la Recherche Scientifique), UMR 7178, IPHC (Hubert Curien Multidisciplinary Institute), Strasbourg, France
| | - Pascale Schwinté
- INSERM (French National Institute of Health and Medical Research), “Osteoarticular and Dental Regenerative Nanomedicine” Laboratory, UMR 1109, Faculté de Médecine, FMTS
- University of Strasbourg, Faculté de Chirurgie Dentaire
| | - Manuel Arruebo
- Department of Chemical Engineering, INA (Aragon Nanoscience Institute), University of Zaragoza, Zaragoza, Spain
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health and Medical Research), “Osteoarticular and Dental Regenerative Nanomedicine” Laboratory, UMR 1109, Faculté de Médecine, FMTS
- University of Strasbourg, Faculté de Chirurgie Dentaire
| |
Collapse
|
47
|
Keller L, Schwinté P, Gomez-Barrena E, Arruebo M, Benkirane-Jessel N. Smart Implants as a Novel Strategy to Regenerate Well-Founded Cartilage. Trends Biotechnol 2017; 35:8-11. [DOI: 10.1016/j.tibtech.2016.05.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 05/12/2016] [Accepted: 05/17/2016] [Indexed: 11/28/2022]
|
48
|
Keller L, Regiel-Futyura A, Gimeno M, Eap S, Mendoza G, Andreu V, Wagner Q, Kyziol A, Arruebo M, Benkirane-Jessel N. Chitosan-Based Scaffold Integration in Mice Calvaria Defect Model: Histopathological Study. J Comp Pathol 2017. [DOI: 10.1016/j.jcpa.2016.11.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
49
|
Wagner Q, Offner D, Idoux-Gillet Y, Saleem I, Somavarapu S, Schwinté P, Benkirane-Jessel N, Keller L. Advanced nanostructured medical device combining mesenchymal cells and VEGF nanoparticles for enhanced engineered tissue vascularization. Nanomedicine (Lond) 2016; 11:2419-30. [PMID: 27529130 DOI: 10.2217/nnm-2016-0189] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
AIM Success of functional vascularized tissue repair depends on vascular support system supply and still remains challenging. Our objective was to develop a nanoactive implant enhancing endothelial cell activity, particularly for bone tissue engineering in the regenerative medicine field. MATERIALS & METHODS We developed a new strategy of tridimensional implant based on cell-dependent sustained release of VEGF nanoparticles. These nanoparticles were homogeneously distributed within nanoreservoirs onto the porous scaffold, with quicker reorganization of endothelial cells. Moreover, the activity of this active smart implant on cells was also modulated by addition of osteoblastic cells. RESULTS & CONCLUSION This sophisticated active strategy should potentiate efficiency of current therapeutic implants for bone repair, avoiding the need for bone substitutes.
Collapse
Affiliation(s)
- Quentin Wagner
- INSERM (French National Institute of Health & Medical Research), "Osteoarticular & Dental Regenerative Nanomedicine" Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg Cedex. FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Damien Offner
- INSERM (French National Institute of Health & Medical Research), "Osteoarticular & Dental Regenerative Nanomedicine" Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg Cedex. FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Ysia Idoux-Gillet
- INSERM (French National Institute of Health & Medical Research), "Osteoarticular & Dental Regenerative Nanomedicine" Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg Cedex. FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Imran Saleem
- School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK
| | - Satyanarayana Somavarapu
- Department of Pharmaceutics, School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
| | - Pascale Schwinté
- INSERM (French National Institute of Health & Medical Research), "Osteoarticular & Dental Regenerative Nanomedicine" Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg Cedex. FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Nadia Benkirane-Jessel
- INSERM (French National Institute of Health & Medical Research), "Osteoarticular & Dental Regenerative Nanomedicine" Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg Cedex. FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l'Hôpital, F-67000 Strasbourg, France
| | - Laetitia Keller
- INSERM (French National Institute of Health & Medical Research), "Osteoarticular & Dental Regenerative Nanomedicine" Laboratory, UMR 1109, Faculté de Médecine, F-67085 Strasbourg Cedex. FMTS, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 1 place de l'Hôpital, F-67000 Strasbourg, France
| |
Collapse
|
50
|
Schiavi J, Keller L, Morand DN, De Isla N, Huck O, Lutz JC, Mainard D, Schwinté P, Benkirane-Jessel N. Active implant combining human stem cell microtissues and growth factors for bone-regenerative nanomedicine. Nanomedicine (Lond) 2016; 10:753-63. [PMID: 25816878 DOI: 10.2217/nnm.14.228] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
AIMS Mesenchymal stem cells (MSCs) from adult bone marrow provide an exciting and promising stem cell population for the repair of bone in skeletal diseases. Here, we describe a new generation of collagen nanofiber implant functionalized with growth factor BMP-7 nanoreservoirs and equipped with human MSC microtissues (MTs) for regenerative nanomedicine. MATERIALS & METHODS By using a 3D nanofibrous collagen membrane and by adding MTs rather than single cells, we optimize the microenvironment for cell colonization, differentiation and growth. RESULTS & CONCLUSION Furthermore, in this study, we have shown that by combining BMP-7 with these MSC MTs in this double 3D environment, we further accelerate bone growth in vivo. The strategy described here should enhance the efficiency of therapeutic implants compared with current simplistic approaches used in the clinic today based on collagen implants soaked in bone morphogenic proteins.
Collapse
Affiliation(s)
- Jessica Schiavi
- INSERM UMR1109, Osteoarticular & Dental Regenerative Nanomedicine, Faculté de Médecine, FMTS, F-67085 Strasbourg Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|